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For small diameter (<6 mm) blood vessel replacements, lack of collaterals and vascular 
disease preclude homografts; while synthetic analogs, ePTFE, expanded 
polytetrafluoroethylene, and PET, polyethyleneterephathalate, are prone to acute 
thrombosis and restenosis. It is postulated that the hierarchical assembly of cell populated 
matrices fabricated from protein analogs provides a new design strategy for generating a 
structurally viable tissue engineered vascular graft. To this end, synthetic elastin and 
collagen fiber analogs offer a novel strategy for creating tissue engineered vascular grafts 
with mechanical and biological properties that match or exceed those of native vessels. 
The objective of this work is to develop techniques for the fabrication of prosthetic 
vascular grafts from a series of extracellular matrix analogs composed of nanofibrous 
collagen matrices and elastin-mimetic proteins, with and without cells, and subsequently 
evaluate their biocompatibility and mechanical properties. The first aim relates to the 
fabrication and mechanical analysis of vascular grafts made from aforementioned protein 
analogs. The second aim relates to the seeding and proliferation of rodent mesenchymal 
stem cells on protein-based composites to recapitulate the media of native vasculature. 
The third aim relates to assessing the in vivo biocompatibility and stability of tissue 






1.1 Objective, Hypothesis, and Specific Aims 
 
The objective of this project is to develop techniques for the fabrication of prosthetic 
vascular grafts from a series of extracellular matrix analogs composed of nanofibrous 
collagen matrices and elastin-mimetic proteins, with and without cells, and subsequently 
evaluate their biocompatibility and mechanical properties in vitro and in vivo.  The 
central hypothesis is that by utilizing nanofibrous collagen matrices, recombinant elastin 
mimetic polypeptides and mesenchymal stem cells, the microstructure of blood vessels 
can be recapitulated, resulting in a vascular prosthesis that is mechanically and 
biologically similar to native vasculature and biocompatible.  The specific aims of this 
project were: 
 
Specific Aim I: Develop a strategy for the fabrication of mechanically robust 
collagen nanofiber-elastin vascular conduits.  Synthetic elastin and collagen nanofiber 
analogs provide a new framework for creating tissue engineered vascular grafts with 
mechanical characteristics that match or exceed those of native vessels.  Aligned 
nanofibrous collagen lamellae (25 – 30 µm thick, 60-90 nm fibril diameter) will be 
manufactured by constant strain alignment of collagen gels and subsequent drying, 
detailed in Chapter 2.  Chapter 3 details the development of nanofibrous collagen sheets 
and strategies to tune their mechanical properties by generating structural anisotropy 
within the matrices utilizing microfabrication strategies. Nanofibrous lamellae will be 
embedded in a recombinant elastin matrix, or co-cast from mixtures of collagen and 
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recombinant elastin, to form protein composite sheets.  These sheets will be rolled on a 
4mm mandrel, and individual layers will be reconstituted by thermal cooling and 
reheating, as detailed in Chapter 4. The use of biomimetic protein based polymers, 
collagen nanofibrous matrices and recombinant elastin mimetics attempts to address the 
critical need for small diameter vascular grafts that are mechanically and structurally 
similar to native vasculature over current synthetic substitutes.   
 
Specific Aim II: Develop and optimize a strategy for the modification of collagen-
elastin protein composites to support mesenchymal stem cell growth and 
proliferation.  Mechanically robust protein composite sheets will be constructed in a 
fashion to enhance cell adhesive capabilities of matrices afforded by collagen, which can 
act as a suitable substrate for the adhesion and proliferation of mesenchymal stem cells, 
which can be rolled to form cellularized vascular graft composites.  Collagen-elastin 
composite sheets will be seeded with rodent bone marrow derived mesenchymal stem 
cells (rodent BM-MSCs), cultured to confluence, and rolled on a 4mm mandrel to form a 
cellularized vascular graft.  BM-MSC seeded tubular conduits will be evaluated for cell 
seeding density, proliferation and cell survival.  Protein composites, with the addition of 
mesenchymal stem cells, presents a strategy for the fabrication of cellularized vascular 
grafts that have helically oriented cells and collagen fibers, similar to native blood 
vessels.  Further, in Chapter 4 the development of an optimal cell seeding protocol and 




Specific Aim III: Determine the capacity of acellular and cell-populated 
vascular bioprostheses to resist stenosis, thrombus formation and 
aneurysm formation in vivo.  Cell populated compliance matched media equivalents 
will display enhanced resistance to fatigue related mechanical damage, thrombus 
formation and aneurysm formation in vivo.  Cellularized and acellular collagen nanofiber 
– elastin tubular composites will be fabricated and implanted in a rodent aortic 
interposition model.  Implanted grafts will be analyzed for patency, acute thrombosis and 
chronic pathologies including arteriosclerosis, thrombosis and stenosis.  Further, vascular 
graft remodeling, seeded cell morphology and phenotype, ability to resist tissue 
inflammation and graft mechanics will be evaluated upon explant.  Acute thrombosis and 
chronic restenosis are two of the most common routes for synthetic graft failure, along 
with acute and chronic inflammation. The ability to generate biomimetic and 
biocompatible small diameter vascular prostheses, with or without mesenchymal stem 
cell based media equivalents, which remain patent in vivo, is a tremendous step in the 
development of treatment modalities for small diameter (<6 mm) blood vessel tissue 
engineering, and is further discussed in Chapter 4. Finally, the future of the project, 
eventual goals that we hope to achieve in the long-term and development of a platform 
for studies into higher level constructs for the advancement of vascular tissue engineering 
is discussed in Chapter 5. 
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1.2 Background and Significance 
Cardiovascular disease (CVD) affects over 71 million people in the United States of 
America alone and costs exceed 500 billion dollars annually.  Specific to cardiovascular 
disease in America, the number of annual inpatient visits totaled over 7 million with over 
450,000 in-patient bypass surgeries, caused in part by diet and inherited factors [1].  
Despite improvements in the medical therapy of CVD, the number of vascular 
interventions, including bypass grafting and angioplasty with or without stenting has 
increased in recent years.  Vascular bypass grafting and balloon angioplasty with stent 
placement account for a large number of procedures and are more prevalent in patients 
over the age of 65 years, who are less likely to have sufficient vein for use as a conduit 
for revascularization [2; 3].  Although autologus veins or arteries provide the best patency 
rates for cardiac and peripheral vascular bypass grafting, many patients do not have 
suitable vessels, and autograft suitability may be difficult to define in advance of the 
bypass operation.    
The replacement of large diameter vessels (>6 mm), such as the aorta, has been 
performed successfully with synthetic polymer prosthetics with long-term patency. 
However, most blood vessels within the peripheral, cerebral and cardiac vasculature 






 Reproduced in part from Kumar, VA, Brewster, LP, Caves, JM and Chaikof EL. 
Tissue Engineering of Blood Vessels: Functional Requirements, Progress, and Future 
Challenges. Cardiovascular Engineering and Technology,2,3: 137-148, 2011[4]. 
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Several studies have shown that small-diameter synthetic polymer grafts have 
rapid thrombus formation and intimal hyperplasia subsequent to bypass surgery, limiting 
their utility [3; 5; 6]. These acute and chronic phenomena were localized not only to the 
regions of graft anastomoses but also to the mid-graft region, and these findings may also 
extend to larger diameter grafts [7; 8]. Synthetic vascular grafts also present a continued 
risk of bacterial colonization and subsequent graft infection and, in addition, are capable 
of promoting a low-level, chronic inflammatory response that may contribute to the 
development of neointimal hyperplasia.  Mechanically, the compliance mismatch 
between a prosthetic graft (0.5-1.5%/100 mmHg) and the host artery (5-15%/100 mmHg) 
may also lead to neointimal hyperplasia and late graft failure.  Finally, the inability of 
synthetic grafts to grow and adapt decreases the utility of prosthetic grafts in pediatric 
patients.  
 Motivated by these limitations, the development of a tissue-engineered blood 
vessel (TEBV) has progressed significantly over the past two decades.  In concept, the 
TEBV will closely match the biomechanical aspects of healthy artery and be capable of 
growth, remodeling, and vasoactive responses.  An endothelial cell (EC) layer will 
provide anti-platelet, anti-coagulant and pro-fibrinolytic properties that would decrease 
thrombogenesis and restenosis [9].  
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Functional requirements in blood vessel tissue engineering 
 Requirements for TEBV design may be conceptually divided into the linked areas 
of mechanical and biological performance.  Biological-mechanical interconnectivity is 
often desirable, such as the contractile responses  achieved with some TEBV [10], or an 
observed increase in compliance, from 2 to 9 %/100 mmHg, after 6 months in vivo 
remodeling [11]. However, maladaptive biological responses leading to premature 
biodegradation and mechanical failure are a common consideration for all degradable-
scaffold grafts.    
 
Mechanical requirements.  
International standards for Dacron™ and ePTFE prostheses provide a foundation 
for these requirements, although the complexity of tissue-engineering requires developers 
to look much further [12].  Mechanical considerations include burst pressure, fatigue-
resistance, suture retention, kinking radius, and compliance.  Designers must also 
consider homogeneity over the length of the prosthesis, which may be tens of centimeters 
[13], variations as the implant remodels, and lot-to-lot variability inherent to cell-based 
products.  Despite broad and prolonged interest in this area, standardized mechanical 
targets and protocols are still evolving [14].   
 Testing of burst pressure and mechanical resistance to catastrophic rupture/ 
tearing of the vascular prosthesis is required to ensure the graft can withstand physiologic 
variations in pressure.  For example, the average pressure in the arterial circulation close 
to the heart is 100 mmHg, but in the femoral or popliteal artery, while standing, is about 
250 mmHg, owing to the contribution of hydrostatic pressure. Conversely, pressures in 
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the cerebral vasculature are generally lower; 60-100 mmHg [15]. However, a 
significantly challenging vessel to replace is the common carotid. This is due not only to 
high flowrates (approximating 200mL/min) but turbulent and recirculating flows at the 
internal/external carotid bifurcation and carotid sinus [15; 16; 17; 18]. Thus there is still 
much debate as to the best approach to treat carotid atherosclerotic disease; stenting, 
endarterectomy, with or without a patch material or bypass grafting [19; 20; 21; 22]. High 
burst pressures are clearly desirable. However, whether TEBV must match native vein, 
artery, or simply be at a level above maximum physiologic pressure remains debated. In 
pigs, investigators have suggested that TEBV with burst pressures as low as 600-700 mm 
Hg can be implanted in the arterial circulation without observed dilatation [23]. Typical 
burst pressure testing involves the steady inflation of a blood vessel/ tissue engineered 
construct to a pressure at which the construct starts to rupture.  Porous constructs are 
tested by inflating either a flexible elastomer, with a stiffness negligible to that of the 
material being tested, in the tubular construct, or sealing the pores of the construct with a 
material of negligible mechanical strength.  Burst pressures are measured with systems 
that apply increasing internal pressure loads, and record outer diameter and internal 
pressure.  Specimens are typically maintained in physiologic buffer (37°C PBS) during 
testing. Of particular note is the inflation rate to bursting of tissue engineered constructs: 
typical inflation rates that compensate for potential creep and stress relaxation of 
materials in a physiologic setting have been established to be around 0.2 mL/s [24].  
However, faster inflation rates have been shown to drastically increase the expected burst 
pressure, as the material rapidly inflates with little to no deformation.  Further, it is 
important for grafts to remain fatigue resistant, ensuring their structural components and 
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mechanical properties do not alter with repeated cycling in a pulsatile flow setting [25; 
26]. Notably, extrapolation of burst pressure from the ultimate tensile stress of flat strips 
or ring specimens may over-estimate direct burst pressure measurements [14]. 
Interestingly, for specific TEBV systems non-invasive prediction of burst pressure from 
stiffness measurements at low pressures has been demonstrated [27]. Typical burst 
pressures of native vasculature and synthetic alternatives are shown in Table 1.1. 
 Compliance and fatigue may be evaluated with similar test fixtures.  Compliance 
is calculated from the percent change in internal radius over a physiologic range of 
pressure (80-120 mmHg) and is often expressed in units of %/100 mmHg.  The 
pressurized inner radius must often be calculated from images of the pressurized outer 
diameter, the inner diameter at rest, and the assumption of incompressibility of the graft 
wall. Typical compliances are dependent on the locale of the vessel, arterial, venous or 
synthetic, detailed in Table 1.1 [2; 28; 29; 30; 31]. Similar to burst pressure, the 
mechanical response of constructs is dependent on the rate at which scaffold inflation is 
performed due to time-dependent phenomena such as stress relaxation [24; 32; 33]. 
Further, it is critical to evaluate the compliance of tissue constructs in physiologically 
relevant conditions that simulate the native environment: flowrates, flow medium, 
pulsatile flow, pressure gradients and temperature.  The reader is directed to the 
following references for further vessel specific mechanical properties [2; 28; 29; 30; 31]. 
Fatigue testing may consist of sustained static, cyclic, or stepwise pressures profiles, 
followed by an assessment of the burst pressure or compliance to monitor any change 
from initial strength.  Although the importance of short-term fatigue tests is clear, when 
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significant biodegradation and remodeling is anticipated the predictive value of long-term 
in vitro fatigue tests may be limited.  
Suture retention strength is measured by placing a suture 2 mm from the end of a 
vessel specimen and measuring the force required to dislodge the suture in a 
physiologically relevant condition and rate: 1 mm/s, 37˚C [12].  Typical suture retention 
strengths of native vasculature range widely depending on vessel type (Table 1) [31; 32; 
34; 35; 36; 37].       
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Table 1.1: Mechanical properties of common blood vessels and current synthetic 
replacements. Ranges represent average values from cited studies. 
 








Coronary: 8.0-17.0 [38; 39],  
Carotid: 5.0-14.7 [40; 41],  
Femoral: 6.0-14.1 [42; 43],  
Popliteal: 4.7-8.5 [42],  
Internal thoracic artery:6.5-12.0 




Saphenous: 0.7-2.6 [34; 40; 44],  
Umbilical: 1.5-3.7 [40; 46] 
180-250 [34; 45; 
47] 
1600-2500 [34; 
44; 45; 47] 
Synthetic grafts 
PTFE: 0.2-0.9 [40; 48],  






Biological failure occurs due to different modes depending on whether it occurs 
acutely, over the first weeks/months, or longer-term over months to years.  The acute 
response is usually characterized by blood material interactions that lead to non-specific 
protein adsorption and subsequent blood clotting or thrombosis on the graft luminal 
surface. The chronic response to vascular graft implantation is determined in part by the 
remodeling of the implant, as pannus tissue grows in from the anastamotic regions or 
transmurally, and long term material interactions with the host, such as biodegradation 
and scar tissue formation [52; 53; 54]. 
Of note is the small population of patients that have infection during implantation 
(eg.Staphylococcus epidermidis) which typically populates the anastamotic regions of a 
graft and is estimated to be as high as 1-6% [55]. 
The generation of a luminal layer that prevents non-specific protein adsorption 
and a subsequent immune response is a significant problem that has challenged the field 
till present, especially with the current synthetic standard of care which uses hydrophobic 
materials that present surfaces that are entropically more favorable for blood protein 
adsorption than hydrophilic surfaces.  However, to circumvent the potential for thrombus 
formation, novel biomaterials strive to combine hydrophilicity and resistance to protein 
adsorption through surface modifications or the use of a luminal layer of endothelial 
cells. A quiescent EC layer has been shown to be vital to promoting an (i) anti-platelet, 
(ii) anti-coagulant and (iii)pro-fibrinolytic surface [56; 57; 58; 59; 60; 61].  Conversely, 
occlusion due to activation of the present or neo-endothelial cells is of major concern [6; 
61; 62; 63; 64]. 
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Biochemical and chemical modifications, including homing of cells using CD34 
antibody conjugated to graft surfaces, stromal derived factor-1 (SDF-1) an inducer of 
endothelial progenitor cell migration from the bone marrow, and plasma treatment of 
surfaces facilitate neo-endothelialization of vascular grafts.  Although the source of the 
repopulating EC is still debated (bone marrow endothelial progenitor cells/circulating 
progenitor cells/ECs from the nascent vasculature), endothelial cells play a pivotal role in 
the biocompatibility of blood-contacting materials.  Moreover, the former strategies of 
creating a homing-like environment for cell adhesion and localization is preferred for an 
“off-the-shelf” product that does not require pre-seeding with ECs that often have limited 
proliferative potential due to the age of the patient and the time required for EC isolation, 
culture, seeding and preconditioning to ensure seeded cells do not slough off in a 
hemodynamic environment [65; 66]. Recent canine and baboon studies have suggested 
that immediate recapitulation of the EC layer in vitro or soon after in vivo implantation 
may not be required for short term (6month) graft performance [45], but is still thought to 
be essential for long term graft survival [67; 68; 69].  
Smooth muscle cells (SMC) represent another important cellular component of 
the vascular wall. In normal pulsatile blood flow, the SMC layer contributes to the 
vascular tone and medial compliance of the vessel. However, in a variety of specific 
disease states, they are indicated in the progression of atherosclerosis through myointimal 
hyperplasia [70]. Although much work has focused on the use of luminal EC seeded 
grafts, SMC seeded grafts have shown the potential for improved host integration, 
increased medial contractility, and medial cellularization [71]. Additionally, several 
groups have shown the importance of SMC to aid in the development of the vascular 
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media which is essential for biomechanical function of the vessel. Specifically, they have 
shown SMC secretion and rearrangement of the matrix into helical or circumferential 
orientations, more closely mimicking native structure [10; 72; 73]. Similar to the need to 
maintain a quiescent state for endothelial cells, the phenotypic expression of smooth 
muscle cells is critical to recapitulation of medial function. When SMCs are expanded in 
culture prior to seeding, they frequently adopt a non-contractile, proliferative, synthetic 
phenotype due to the loss of actin filaments [74; 75]. Development of a contractile SMC 
phenotype depends on a milieu of factors including local stress/strains, growth factors, 
and paracrine/ autocrine signaling [76; 77]. Correct phenotype is essential in preventing 
medial thickening and intimal hyperplasia from proliferative SMCs. The reader is 
referred to a review by Chan-Park et al for more details [78]. A variety of other cell 
types, both native and non-native to vasculature have been used for repopulation of tissue 
engineering vascular grafts. Of note, work with stem cells, including endothelial 
progenitor cells and mesenchymal stem cells, umbilical cord cells and peritoneal cells is 
discussed in detail herein. 
Mediation of the immune response due to surgical trauma and foreign body 
reaction is critical to graft performance.  Several groups have attempted to create 
functional tissue replacements that serve to passively prevent acute and chronic rejection.  
This has been done through the incorporation of bioactive materials, tailoring of 
degradation of biodegradable polymers to leach minimally cytotoxic degradation 
products, and incorporation of biomimetic moieties, such as collagen, elastin, and 
glycosaminoglycans [2; 3; 79; 80; 81; 82; 83; 84; 85]. However, there has been a recent 
trend to actively modulate the inflammatory response of tissue replacements by 
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incorporation of moieties that strive to curtail adverse inflammatory responses such as 
neutrophil invasion, macrophage polarization and modulation of the adaptive immune 
response, notwithstanding the use of immunocompromised animal models [86; 87; 88]. 
Further, recent studies have demonstrated the importance of ensuring that the local 
environment of the graft is maintained to be non-inflammatory. Specific to macrophage 
polarization, Ariganello and colleagues have shown the utility of decellularized matrices 
to direct macrophage polarization to a non-inflammatory phenotype that would promote 
healing and resolution, instead of inflammation [89; 90]. The incorporation of bone 
marrow mesenchymal stem cells (BM-MSCs) within tissue engineered and biodegradable 
scaffolds has been widely reported. Specific to vascular grafts, bone marrow derived stem 
cells have been shown to differentiate into endothelial progenitor like-cells [91; 92; 93; 
94], as well as other vascular wall cellular constituents,  smooth muscle cells [95; 96]. In 
addition to repopulating ECM-based scaffolds, MSC have also been shown to attenuate 
the inflammatory and immune responses associated with surgical trauma and implants. 
MSC have the ability to direct macrophage polarization toward an M2 phenotype 
(healing/ resolution) over an M1 phenotype (inflammatory), down-regulate MHC, major 
histocompatibility complex, and co-stimulatory molecule expression, decrease 
inflammatory cytokine expression (TNF-α, IL-12, IFN-γ), increase anti-inflammatory 
cytokine expression (IL-10), promote T-regulatory cell proliferation and interfere with 
lymphocyte replication [97; 98; 99; 100; 101; 102]. 
In vitro tests for TEBV include standard biocompatibility assays and, depending 
upon the design concept, may extend to consideration of cell supportive properties, 
hemocompatibility, and vasoactivity.  Cytocompatibility is usually established with 
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seeding of human EC, SMC and fibroblasts. To simulate features of the innate immune 
response, groups have used bio-similar environments with the addition of secretion 
products from inflammatory cells, such as macrophages and neutrophils, to simulate 
degradation in vivo and in vitro [6; 30; 54; 103; 104; 105]. In vitro hemocompatibility is 
typically determined with the use of whole blood clotting times, platelet adhesion and 
morphology, and activation states of inflammatory cells on vascular biomaterials in a 
variety of systems: static clotting time / platelet adhesion and morphology assays, flow 
loops and AV shunt models, preceding in vivo implants [6; 31; 106; 107; 108; 109]. 
 In vivo studies typically commence in rodents. Despite small vessels (< 1 mm), 
murine systems provide the potential to test constructs with human cells in nude [110] or 
severe combined immunodeficiency (SCID) mice [111]. Mouse models have been 
developed to incorporate intravital molecular imaging to track labeled cells and protease 
activity [110]. Rat models allow the assessment of human-cell constructs in (immune 
compromised) athymic animals [34], using slightly larger 1-2 mm inner diameter test 
vessels. A recent review highlights pitfalls to anticipate as investigators proceed to large 
animal models [13]. 
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Evolving concepts and current status of TEBV technology 
 Collagen and other biopolymers.  Traditional “cell-plus-scaffold” tissue 
engineering was first applied to blood vessel constructs by Weinberg and Bell in 1986 
[112].  Employing a collagen gel cultured with SMC and EC, they observed a near-
confluent and biologically active EC luminal surface.  However, maximum burst 
pressures in the range of 400 mmHg necessitated the additional support of a Dacron™ 
mesh.  Several other studies have used collagen or other biologically derived blood vessel 
constituents to recapitulate the features of a blood vessel in scaffolds, with limited 
success, given the weak nature of collagen gels [8; 113; 114]. Strategies incorporating 
cells, matrix components and intracellular biomolecules have been shown to improve the 
mechanical strength of collagen-based constructs by compaction and re-organization of 
collagen fibril architecture [115; 116; 117; 118; 119]. In particular, Seliktar et al. have 
demonstrated the ability of seeded cells and mechanical conditioning to rearrange 
collagen fibrils circumferentially, leading to increased strength [120]. Our research group 
has observed high burst pressures using a biomaterial composite consisting of 
crosslinked, oriented collagen microfibers reinforcing a matrix comprised of a 
recombinant elastin analogue [83]. 
 Fibrin is of interest as an alternative biopolymer scaffold due to advantages 
including its natural role in wound healing, widespread clinical acceptance as a tissue 
sealant and the potential for generating an autologous biomaterial from the patients’ own 
blood [121]. Cummings et al. found that while fibrin vascular constructs were weaker and 
more extensible than collagen, fibrin-collagen composites displayed higher strength and 
gel compaction than collagen alone [122]. Fibrin gels have also been shown to stimulate 
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SMC to synthesize elastin, an important component of the artery wall, which is neglected 
in many collagen-based TEBV [123].  Short segments (1.5 - 2.0 cm) of TEBV from fibrin 
cultured with either bone-marrow derived progenitor cells or SMC and seeded with EC 
demonstrated vasoactivity and have been implanted as interpositional grafts in the lamb 
external jugular vein [124; 125]. Recently, a bioreactor design capable of simultaneously 
processing six TEBV from fibrin with human dermal fibroblasts resulted in burst 
pressures of 1400 – 1600 mmHg after 5 to 7 weeks of culture [27]. The resulting 
compliance was 2-5 %/ mmHg and low suture retention strengths were compensated by 
the addition of polymeric cuffs from poly(lactic acid).  Fibrin-based approaches have also 
been augmented through the addition of growth factors via sustained delivery systems in 
order to enhance and sustain cellular in-growth [126]. 
 Biodegradable and bioresorbable synthetic polymers. In addition to 
biopolymers, biodegradable synthetic polymer scaffolds, such as polylactic acid (PLA), 
polyglycolic acid (PGA), polycaprolactone (PCL), polyurethanes (PU), and related 
copolymers or composites have been extensively studied [10; 73; 127; 128; 129; 130; 
131; 132]. Typically these scaffolds are pre-seeded with cells using a variety of 
techniques, including static seeding, dynamic seeding, vacuum aided seeding, or 
electrostatic seeding and conditioned in a bioreactor to ensure the cells can withstand 
physiologic blood flow [133; 134; 135]. In a well-studied example of the biodegradable 
polymer approach, Niklason et al fabricated TEBV using PGA seeded with SMC and 
cultured at 1-2% cyclic mechanical strain in a bioreactor for 7 to 8 weeks, followed by 
EC seeding [10]. Further, Dahl et al report TEBV scaffolds generated from PGA seeded 
with allogeneic SMCs, conditioned in a bioreactor, and subsequently decellularized. 
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Acellular specimens were studied in a baboon AV shunt model, and scaffolds with a 
luminal EC coating were investigated in a canine peripheral and coronary bypass model. 
A potential disadvantage of this strategy is the relatively low levels of endothelialization 
(14±8%) [45].  Further, in a challenging model of porcine carotid grafting, Niklason and 
colleagues showed that decellularized, engineered grafts resisted both thrombosis and 
intimal hyperplasia.  Head-to-head comparisons with autologous vein grafts showed that 
decellularized, engineered grafts had less neointima formation and superior patency rates 
after 30 days.  The etiology of this advantage may be related to decreased activation of 
the mTOR pathway in engineered grafts as compared to vein, though this result remains 
to be confirmed in other studies (personal communication). 
  With respect to the proliferative capacity of the cells used in tissue engineered 
constructs, aging is associated with decreasing telomere length and directly related to 
decreased doubling capacity.   To overcome this limitation, Poh et al. have demonstrated 
an increase in the population doublings of adult VSMCs through retroviral infection with 
the telomerase reverse transcriptase subunit (hTERT) [65]. Despite improvement, 
mechanical strength remained too low, potentially due to reduced collagen synthesis 
[136; 137]. To circumvent the challenges of SMCs, human mesenchymal stem cells 
(MSC) were used in an 8 week protocol involving proliferation and differentiation phases 
[81]. Collagen matrix synthesis and substantial conversion to an SMC phenotype were 
demonstrated, but burst pressures remained at approximately 400 mmHg.  These 
biodegradable systems have confirmed that: (i) non-degraded polymer fragments can 
amplify stresses and dramatically compromise strength; (ii) collagen organization, as well 
as quantity, is required for strength; (iii) low compliance may be due to the absence of 
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organized extracellular elastin sheets, as well as sub-physiologic SMC contractility [138; 
139].    
The vascular tissue engineering system developed by Shin’oka and colleagues 
uses similar biodegradable polymers.  Employing porous ε-caprolactone and L-lactide 
copolymer reinforced with a PGA fabric, seeded with cultured autologous venous cells, 
they reported the first clinically effective TEBV implants [140]. By substituting 
autologous bone-marrow mononuclear cells (BMC), the cell culture step was avoided in 
subsequent implants [132]. Given the cost, delay, contamination potential, as well as 
dependence on xenogenic serums in culture medium, avoidance of prolonged in vitro 
culture represented a significant advantage. Notably, in these reports the TEBV implants 
repaired congenital defects in the pulmonary circulation of a pediatric population, while 
most TEBV applications must address more demanding mechanics of the arterial 
circulation, as well as the limitations of autologous cells obtained from elderly donors.  
Early efforts to adapt the technology to arterial implants have been reported [141]. 
Despite initial suggestions that BMCs differentiate and proliferate as the TEBV is 
incorporated [132; 142], recent analysis in SCID/beige mice found no evidence that the 
implanted cells persist longer than about one week [87]. BMCs appear to accelerate in 
vivo remodeling by paracrine recruitment of host monocytes. The authors also suggest 
that, in turn, accelerated monocyte infiltration triggered enhanced repopulation by host 
SMC and EC. Regardless of technique employed, the persistence of seeded cells and the 
ability to withstand hemodynamic forces (shear in the lumen or compressive in the 
vascular wall), remaining a desired phenotype, or differentiation along specific lineages 
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(for stem cells), and maintenance of viable cytokine/chemokine expression, is critical to 
graft success [86; 135; 143].    
Bioresorbable vascular grafts are incorporated into the recipient through host 
mediated degradation systems that include enzymolysis, oxidation and hydrolysis, while 
allowing for concomitant repopulation of the scaffold with native cells. Wolfe et al have 
shown that bioresorbable electrospun polydioxane (PDO) or PCL scaffolds elicited 
varying tissue factor expression when exposed to monocytes; demonstrating no greater 
risk of thrombotic occlusion than ePTFE [144]. Other groups have used a variety of 
bioresorbable polymeric constructs showing mechanical and biological utility [2; 145; 
146; 147]. Campbell et al have developed an interesting technique wherein the host’s 
peritoneal cavity is used as a bioreactor to construct hierarchical tissue. They implanted 
silastic tubing in the peritoneal cavity of rats and rabbits for 2 weeks, which resulted in 
scaffolds that had developed layers of ECM, and were populated with myofibroblasts and 
mesothelium. 10-20 mm long grafts were subsequently implanted in the host animal, with 
greater than 4month patency. Their technique has been extended to the development of a 
variety of soft tissues including vas deferens, bladder and uterus [148; 149]. Vito’s group 
has developed a method for the in vivo or ex vivo stretching of arterial segments in 
suitable media conditions for generation of blood vessels. They have studied several 
aspects of the biomechanical regimes that effect remodeling and growth of vessels [150; 
151; 152; 153]. These studies were further carried into collagen based gels which have 
been seeded with cells and show morphological changes in ultrastructure and cellular 
behavior as a function of mechanical conditioning [120]. 
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Cell-sheet tissue engineering.  TEBV fabricated from cell sheet-based tissue 
engineering consist entirely of autologous cells and secreted matrix proteins. Initially, 
sheet-based TEBV consisted of SMC or fibroblasts cultured with ascorbic acid for 
approximately 30 days to form cohesive sheets [9]. The SMC sheet was wrapped about a 
tubular support to create the vessel media, matured for one week, wrapped with a 
fibroblast-sheet “adventitia,” matured for 7 weeks, and then seeded with EC. This process 
was replaced with a scheme consisting of a decellularized internal membrane fabricated 
from a fibroblast sheet, a living adventitial layer, and a seeded endothelial layer, requiring 
a total of 28 weeks of culture [34]. This design demonstrated favorable mechanics for 
implantation in the arterial circulation, and these TEBV have been successfully implanted 
as arteriovenous fistulas in high-risk patients [154]. This groundbreaking progress with a 
sheet-based tissue engineering system has been encouraging, although long culture times 
remain an important factor in keeping costs high and limiting application to non-urgent 
indications. Similar work has been done by other groups that have developed rolling 
techniques with localized regions of specific cell types or synthetic/biosynthetic materials 
such as PLLA, collagen and elastin [83; 86; 155]. 
Decellularized tissue scaffolds.  This technique maintains the native extracellular 
matrix proteins that provide both structural integrity and instructive cues for cellular 
ingrowth.  By incubating bone marrow derived cells in decellularized canine carotid 
arteries, Cho et al. demonstrated cellular incorporation into the scaffold and subsequent 
differentiation of these cells into endothelial and vascular smooth muscle cells and 
subsequently into 3 distinct vessel layers [95]. Zhou et al have shown that heparin and 
VEGF modified decellularized canine carotids grafts have higher 6 month patency rates 
 22 
than unmodified grafts [156]. In a similar study, Zhou et al showed that heparin 
immobilized on decellularized grafts implanted in rats supplemented with 14days of 
granulocyte-colony stimulating factor had higher patency and lower neointima formation 
compared to controls; due to homing of circulating EPCs to the graft surface, 
demonstrating the potential for cytokine treatment post surgical intervention [157]. 
Further, potential changes in the long term mechanical response associated with 
decellularization protocols, specifically the shape of the pressure-diameter curves, and 
how they relate to compliance is of concern [158].  Other decellularized tubular conduits 
have been investigated for vascular tissue engineering. Specifically, aorta [159; 160], 
umbilical arteries [5], saphenous vein [47], ureter [161; 162], and small intestinal 
submucosa (SIS) [163; 164] to name a few. Clarke et al report vascular grafts from 
decellularized bovine tissue that show high patency in a canine model, with host cell 
repopulation of the prosthesis [165]. Further, decellularized bovine ureter, has shown the 
potential to be used in humans as a blood vessel replacement. However, early results 
show the potential for aneurysm formation [166], poor long term patency as hemodialysis 
access shunts, (14% at 1year) [167], similar to ePTFE access grafts [168]; and infection 
and inflammation due to potential residual xenoantigen [169]. 
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Translational challenges  
At present, TEBV use in humans has required at least a bone marrow aspiration 
and brief cell seeding for pediatric pulmonary artery replacement and up to 28 weeks of 
maturation of rolled fibroblast sheets to withstand arterial pressures for use as 
arteriovenous conduits in patients requiring dialysis.  Advanced cell or biomaterial 
technologies may drive the next generation of solutions.  In particular, the recent 
recognition that BMC are likely to survive only transiently and cellular repopulation is 
driven by monocyte infiltration may suggest new cell and biomaterial strategies for 
TEBV researchers [87]. In addition, early results translating biodegradable polymer 
scaffold systems to the arterial circulation in mice suggest that protocols requiring as 
little as 1 week maturation in culture may be attainable [141].   
Research timeline, regulatory, and economic issues.  McAllister et al. have 
argued that the unique challenges inherent to translating cell-based therapies, including 
tissue-engineering, will benefit from the application of several distinct strategies [170]. In 
particular, the authors note that researchers should include an early focus on proof-of-
principle with human cells and anticipate an extended (20 year) R&D timeline.  A focus 
on modeling the cost-effectiveness of the technology is emphasized, but not until later in 
this timeline, as clinical trials are planned.  Regulatory approval pathways for tissue-
engineered products are still evolving, and the cost of quality assurance is expected to be 
a challenge given the small lot sizes of tissue-engineered products [171]. 
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Summary and future directions 
 The design of a tissue engineered vascular graft to supplant the diseased arteries’ 
function requires consideration of mechanical, biological and clinical factors that 
influence behavior in vitro and in vivo. To date, tissue engineered products have yet to 
replace the current “gold standard” of an autologous artery or vein. Mechanical 
considerations include (i) a sufficient burst pressure to prevent catastrophic failure of the 
vessel and long-term fatigue resistance, (ii) a suitable compliance that approximates that 
of the vessel to prevent mechanical mismatch, and (iii) a strong enough suture retention 
strength to permit implantation and tolerate hydrodynamic and mechanical forces at the 
anastomoses. Biological and clinical considerations include (i) generation of a non-
fouling luminal surface to prevent thrombosis, (ii) mediation of the immune response due 
to surgical trauma and potential graft rejection and regeneration, and (iii) evaluation in an 
in vivo environment. 
 Several groups have demonstrated the efficacies of various strategies that range 
from modification of existing ePTFE/Dacron™ grafts to acellular/cellularized constructs 
to de novo engineering of tissue substitutes that mimic native vessels. TEBV derived 
from cell-sheet tissue engineering and degradable synthetic polymer scaffolding have 
demonstrated early clinical success and continued progress with several additional 
systems suggests that these technologies will continue to evolve. Clinical success will be 
determined by utilizing a “bottom-up” approach wherein recapitulation of the 
fundamental features of the vascular wall, incorporation of key elements that obviate 
thrombosis and acute graft failure, and potentially a cellular component that will direct 
the unavoidable inflammatory response towards healing. 
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CHAPTER 2 
Fabrication and Characterization of Large Scale Structurally and 





Collagen based scaffolds have been widely used in tissue engineering due to their 
versatility and ease of production [172; 173].  Collagen, typically isolated from an animal 
source (for example: rat tail tendon, calf skin and others) can be solubilized and purified 
by acid extraction from tissue, which preserves the monomeric protein structure; or by 
enzymatic digestion of collagen, which leads to removal of telopeptides vital to 
reorganization of the collagen molecule [174; 175; 176].  Alone or in combination with 
other biomolecules, collagen matrices have been processed into a wide variety of tissue 
substitutes used widely in cardiovascular, musculoskeletal, neural and dermal tissue 
engineering [173; 177; 178].  The ability to modulate the mechanical and physical 
properties of collagen based scaffolds is critical to its utility.  Further it is critical to 
mimic tissue structure to ensure that regeneration of native tissue is guided and supported 
during implant healing. 
 
Although of significantly less tensile strength and stiffness as compared to many 
synthetic non-degradable and biodegradable polymers such as PE (polyethylene), PTFE 
(polytetrafluroethylene), or PLGA (poly-lactic-co-glycolic acid), collagen and other 
biologically derived polymers offer significant advantages related to decreased 
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immunogenicity, increased homology to native structures, and “in-built” cell recognition 
regions [172; 175].  Additionally, several groups, and this report, have shown the ability 
to tailor the mechanical response of collagen, based on the requirements of the tissue to 
be replaced, depending on choice of processing techniques, crosslinker and fabrication 
schemes [179; 180; 181; 182; 183]. 
 
Being the most abundant protein in mammalian systems, collagen is the primary protein 
constituent of many tissues, from blood vessels to bone and skin.  The Type I collagen 
molecule, part of the fibril forming collagen family, is comprised of a tripeptide repeat of 
the amino acids Glycine-Proline-Hydroxyproline, although the latter two have some 
heterogeneity.  Type I collagen further forms a coiled coil structure that leads to the 
formation of fibrils approximately 300nm in length and 5nm in diameter. Further, 
staggered linear stacking of collagen molecules with characteristic 67nm gaps allows for 
native collagen structure staining and identification [174; 176].  Owing to the complex 
nature of the molecular and supramolecular arrangement of collagen, fibrillar collagens 
are able to withstand high tensile/compressive stresses [184; 185].  The higher order 
supramolecular arrangement of collagen structures in vivo, for example in blood vessels, 
confers support and resistance to bursting, while providing little stiffness in the 
physiologic regime due to crimping of collagen fibers [139; 182; 186]. 
 
Fibril alignment, density and microstructure affect mechanical properties by directing 
load and distribution of stress, as well as by providing compliance and resilience to 
engineered constructs and native tissue.  Several investigators have commented on the 
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need for aligned collagen matrices [187; 188; 189; 190; 191; 192].  Specifically, quoting 
Guo & Kaufman, “an easy and effective way to make highly oriented collagen gels with 
no specialized equipment has not yet been demonstrated,” further underscoring the 
importance and need for aligned collagen matrices [187]. To this end, several groups 
have attempted a variety of techniques to align collagen matrices. Given the negative 
diamagnetic anisotropy of collagen molecules, one of the earliest reports of alignment of 
collagen was performed using a magnetic field.  Studies by Chen et al [193], Torbet and 
Ronziere [189] and Tranquillo’s group [194; 195; 196; 197] have reported collagen 
alignment using magnetic fields.  The primary disadvantage is that the strength of the 
magnetic field required for collagen alignment is on the order of 1-10 Tesla, higher than 
that required for MRI, and thus proving to be prohibitively costly.  To circumvent the 
need for such high magnetic fields, other groups have used additives to collagen to assist 
in alignment of collagen fibrils.  Cheng and Kaufman used magnetic beads with modified 
surface functionalities in a weaker magnetic field (10-4T) to align thin (order of µm) 
collagen gels.  However, the potential for leaching of the additives, and concomitant 
cytotoxicity may be prohibitive in vivo [187]. Another method to align collagen 
molecules is through the use of microfluidics.  Lee et al have reported the production of 
aligned collagen molecules in microfluidic channels.  Since the collagen was gelled prior 
to flow into microchannels, there is the likelihood of a fibril density gradient forming 
during collagen gelation in the channels during flow, notwithstanding concerns including 
removal of the collagen from the channels, as well as scaled up manufacturing of larger 
constructs [198], similar to work by Guo et al [187].  Cheng and colleagues have been 
able to use an electrochemical field to align collagen molecules.  This technique, 
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however, has shown only modest alignment with lack of characteristic collagen D-
periodicity in fibers that are 50-400 µm in diameter and inches in length.  However, 
interestingly, they and other groups have reported aligned matrices were significantly 
stronger than unaligned matrices, demonstrating the increase in strength in aligned 
fibrillar collagen matrices [185; 199].  Deitch et al report a novel method to make aligned 
collagen matrices using conventional printing technology, whereby collagen is loaded 
into an ink cartridge and printed onto a glass substrate.  Although novel, this technique 
has yielded thin films, which lack consistency and precise molecular alignment. Further, 
of concern is that the heat generated by the inkjet printer may denature the collagen 
[200]. Vader et al report a novel methodology that employs strain induced alignment of 
small regions of collagen gels that are of approximately 1mm thickness, by pulling apart 
glass pipets [201]. However, we have developed a novel large-scale alignment technique 
that allows for the rapid generation of aligned collagen constructs, suitable for tissue 
engineering.  Further, through the variation of concentration, buffers, temperature of 
gelation, thickness of constructs and fabrication schemes; high density nanofibrous 
collagen matrices that have strengths that approximate and supersede that of most 




2.2 Materials and methods 
 
All chemicals were purchased from Sigma-Aldrich, unless otherwise stated. 
 
Isolation and purification of monomeric collagen. Monomeric Type I rat tail tendon 
collagen was obtained by acid extraction from Sprague-Dawley rats (Pel-Freez 
Biologicals, Rogers, AR) following a procedure adapted from Silver and Trelstad [202].  
Briefly, rat tail tendons were extracted with the aid of autoclaved pliers and dissolved in 
10mM HCl for 4 h at 25˚C to dissolve the proteinaceous components.  Insoluble tissue 
and other contaminants were removed by centrifugation at 30,000g at 4˚C for 30 min 
with subsequent vacuum filtration through 20 µm, 0.45 µm and 0.2 µm filters.  The 
sterile filtered collagen in HCl was precipitated from solution by adding NaCl to a final 
concentration of 0.7M.  The precipitated collagen was pelleted by centrifugation, 
redissolved in 10mM HCl and dialyzed first against 20mM phosphate buffer at room 
temperature, then at 4˚C, second against 10mM HCl at 4˚C and finally against deionized 
water at 4˚C.  The collagen was lyophilized and stored at 4˚C until use. 
 
Production of collagen mats. Monomeric rat tail tendon collagen dissolved in 10mM 
HCl, at concentrations of 0.3125 mg/mL - 2.5 mg/mL, was neutralized using a gelation 
buffer (4.14 mg/mL monobasic sodium phosphate, 12.1 mg/mL dibasic sodium 
phosphate, 6.86 mg/mL TES (N-tris (hydroxymethyl) methyl-2-aminoethane sulfonic 
acid sodium salt, 7.89 mg/mL sodium chloride, pH 8.0) at 4˚C for 24 h. Gels were 
subsequently placed in a fiber incubation buffer (7.89 mg/mL sodium chloride, 4.26 
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mg/mL dibasic sodium phosphate,10 mM Tris, pH 7.4) at 37°C for 48 h to promote 
fibrillogenesis [203]. Gels were then dried at room temperature under a steady air stream. 
 
Generation of structural anisotropy. Collagen gels (100 x 80 x 4 mm) were adhered 
onto 125 µm thick plastic frames, and mounted onto a motorized vertical stretching 
device (Figure 2.1). The stretcher was expanded uniaxially at 3 µm/s and 300 µm/s to 
strains of 0, 10, 20% in deionized water, 25°C.  Strains larger than 20% resulted in 
tearing of the collagen gels.  Aligned gels were then air dried under constant tension for 
24 h at 25˚C, resulting in a dense collagen mat. 
 
Imaging of collagen fibril orientation, morphology and ultrastructure. Dry collagen 
lamellae were hydrated in water for 24 h and subsequently processed for SEM imaging.  
Briefly, samples were dehydrated in serial exchanges of acetone-water mixtures from 
30%-100%.  The samples were then critical point dried, sputter coated with gold and 
imaged at an accelerating voltage of 10 keV using a field emission scanning electron 
microscope (Joel DS 150, Tokyo, Japan).  Scanning electron microscopy, SEM, images 
were taken at 10,000X magnification for alignment and 50,000X magnification for fibril 
diameter measurements.  To determine the ultrastructure and presence of D-periodicity in 
the fibrils, hydrated samples were prepared for transmission electron microscopy (TEM).  
Briefly, samples in PBS were washed in 0.1M cacodylate buffer and fixed in 
glutaraldehyde.  After washing in water, samples were partially dehydrated in ethanol and 
stained with uranyl acetate.  Samples were then fully dehydrated in ethanol, embedded in 
resin and polymerized.  60-80 nm sections were then cut using a RMC MT-7000 
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ultramicrotome (Boeckeler, Tucson, AZ).  Sections were then post stained with uranyl 
acetate and lead citrate and imaged using a JOEL JEM 1210 TEM (JOEL, Tokyo, Japan) 
at 90 kV.  
 
Quantification of alignment. Alignment was determined using Fast Fourier Transforms 
of 10,000X SEM images in ImageJ®.  Uniformity of alignment was determined by 
analysis of various parts of each sample, and amongst various sections of the sample.  
The relative frequency of fibrils in any given angle was determined,divided into 5˚ bins 
of angles and plotted.  The plots were then fitted with a Gaussian distribution to 
determine the peak relative frequency of fibril alignment, and full width at half maximum 
(FWHM), corresponding to the angles between which most of the fibrils are distributed. 
 
Crosslinking and mechanical testing of constructs. Anisotropic and isotropic collagen 
lamellae were crosslinked in a biocompatible crosslinker, genipin-PBS (Fisher Scientific) 
at 6 mg/mL for 24hours at 37˚C. Samples were then cut into 20mm long x 5mm wide 
rectangles that were mounted onto a Dynamic Mechanical Thermal Analyzer V (DMTA 
V, Rheometric Scientific, Piscataway, NJ) with a gauge length of 10 mm, immersed in 
PBS at 37˚C and preconditioned 15 times to 66% of the average maximum failure strain 
for the sample, and then tested to failure at 5 mm/min. A total of 8 samples were tested 
for each group. Thickness of hydrated sample was measured using optical microscopy 
and then correlated to mechanical data to determine the ultimate tensile strength and 




Statistical Analysis. Means and S.D. were obtained for all measurements, image 
analyses and mechanical data. Comparisons will be made using the Student’s t test for 
paired data, ANOVA for multiple comparisons, with Tukey post hoc analysis for 
parametric data.  Nonparametric tests will be carried out using the Kruskal-Wallis 






Rapid generation of high density collagen mats. We have shown the ability generate 
large (centimeter scale) collagen matrices that can be mechanically tuned and 
anisotropically defined. Type I collagen was isolated from rat tail tendon and confirmed 
for purity by PAGE gel analysis.  Collagen gels were structurally aligned, analyzed for 
native ultrastructure and tested for mechanical strength.  Gels were synthesized at a 
variety of concentrations (0.3125 mg/mL, 0.625 mg/mL, 1.25 mg/mL and 2.5 mg/mL) by 
neutralization in a phosphate buffer for 24 hours at 4˚C. Gel thickness was determined by 
the volume of total solution in 10 cm x 8 cm rectangular molds, Figure 2.1 A.  
Fibrillogenesis within collagen gels was enhanced by incubation in a fiber incubation 
buffer for 48 hours at 37˚C, Figure 2.1 B. For alignment of collagen matrices, gels were 
mounted on a axial stretcher and stretched to 0, 10, 20% strain at 3 or 300 µm/s, Figure 
2.1 C & D. Collagen gels were subsequently air dried to less than 1% of their initial 
thickness under a constant air stream, generating collagen mats. We have thus 
demonstrated a technique for the development of collagen matrices with structural 
anisotropy in a scalable method, generating large centimeter scale non-denatured 




Figure 2.1: Schematic of the mechanical setup used to induce strain alignment of 
collagen gels. Collagen gels were cast in a rectangular mold (Length x Width x 
Thickness: 100 x 80 x 4 mm) at 4°C (A), incubated in a fibril incubation buffer for 48 h 
at 37°C (B), mounted on a motorized stretcher (C), and stretched to a strain of 0%, 10% 





Figure 2.2: Ultrastructure of collagen matrices.  Scanning electron micrographs 
showing (A) isotropic microstructure (scale bar: 1 µm), (B) with 83.1 ± 9.44 nm fibrils 
(scale bar: 200 nm). Transmission electron micrographs showing (C) a dense fibrillar 
matrix (scale bar: 1 µm) and (D) native collagen banding showing preservation of the 





Fibrillar microstructure and preservation of native collagen structure. 
Ultrastructural analysis of collagen lamellae showed uniformity of collagen fibril 
diameter for unaligned and aligned gels. 10kX SEM images of critical point dried 
collagen matrices show uniformity and isotropy of unaligned matrices (Figure 2.2 A). 
50kX magnification SEM images of critical point dried collagen matrices were used to 
measure collagen fibril diameter, Figure 2.2 B.  Fibril diameter for unaligned 2.5 mg/mL 
gels was 83.1 ± 9.44 nm, for 1.25 mg/mL gels was 75.7 ± 14.8 nm and for 0.625 mg/mL 
gels was 74.3 ± 11.4 nm.  Fibril diameter for 20% aligned 2.5 mg/mL gels was 78.2 ± 
17.0 nm, for 10% aligned 2.5 mg/mL gels was 81.7 ± 14.8 nm and for 20% aligned 
0.3125 mg/mL gels was 88.52 ± 11.7 nm, which showed no significant difference with 
alignment, stretch amount, stretch rate or concentration. TEM images of uranyl acetate 
stained collagen lamellae showed characteristic D-periodicity, 67 nm collagen banding 
patterns (Figures 2.2 C & D).  Concentration variation did not significantly affect the 
fibril diameter or the ultrastructure of the collagen gels (Table 2.1). Through the 
neutralization of collagen gels using a phosphate based buffer, subsequent incubation 
with fibril incubation buffer to promote fibrillogensis of collagen fibrils, and drying into 
dense matrices, collagen lamellae which resemble native matrix in macro- and ultra-




Figure 2.3: Stretching rate, strain amount and concentration dependence on alignment of collagen matrices. Top panel shows 
SEM images, and bottom panel shows histograms of FFT analyses of SEM images of 9 regions of 4 independent samples, of  (A & D) 
2.5 mg/mL matrix aligned at 300 µm/s to 10% strain, (B & E) 2.5mg/mL matrix aligned at 3 µm/s to 10% strain and (C & F) 2.5 
mg/mL matrix aligned to 20% strain. Scale bar: 500 nm
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Generation of structural anisotropy within collagen matrices. To enhance tissue 
mimetic architecture, it is required that matrices exhibit mechanical anisotropy to ensure 
matching of tissue based replacements.  Subsequent to treatment in fiber incubation 
buffer gels were adhered onto plastic frames and mounted on an automated motorized 
stretching device (Figure 2.1 C).  Higher stretching rates (300 µm/s) resulted in an 
inability to generate structural anisotropy (Figure 2.3 A and Table 2.1). Lower stretching 
rates (3 µm/s) resulted in distinct fibril reorganization into defined structures (Figures 2.3 
B & C, Table 2.1). FFT analysis of 10kX SEM images of collagen lamellae yield relative 
frequencies of fibrils from the horizontal axis. Fibril relative frequencies were summed in 
5 degree increments and histograms were plotted as a function of angle, Figures 2.3 D-F. 
Histogram plots were then fitted with a Gaussian curve and FWHM was subsequently 
determined. FFT analysis of 10kX magnification images of 300 µm/s strained samples to 
10% or 20% showed no preferential alignment of collagen fibrils, Figure 2.3 D. 
Depending on the strain amount, 10% or 20%, the degree of alignment varied at a lower 
strain rate of 3 µm/s, Figure 2.3 E & F. Maximum alignment was achieved with 20% 
strain at a rate of 3 µm/s. Concentration variation did not significantly affect the amount 
of alignment, or the maximum alignment, Table 2.1. Alignment for 2.5mg/mL gels 
strained to 10% at a rate of 3 µm/s had a maximum of 5.64% with a FWHM of ± 37.5˚. 
Alignment for 2.5 mg/mL gels strained to 20% at a rate of 3 µm/s had a significantly 
higher maximum of 6.86% with a FWHM of ± 35.2˚, Figure 2.4. We have thus shown the 





Figure 2.4: Alignment of collagen fibrils based on Gaussian fit of alignment data derived from FFT of SEM images at 10kX 






Figure 2.5: Mechanical properties of 20% stretch aligned, 20% stretch aligned tested perpendicular to alignment, 10% stretch 
aligned and (0%) unaligned 2.5 mg/mL collagen mats. (A)Tensile strength, (B) Strain at failure and (C) Young’s modulus, (D) 
Fibril diameter and (E) Lamella thickness. (A) Tensile strength and (C) Young’s moduli depend on percent alignment of matrices. (B) 
Strain to failure, (D) Fibril diameter and (E) Lamella thicknesses are similar for all constructs. Data presented as mean ± s.d. *p < 0.05  
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Mechanical strength of collagen matrices with and without alignment. In order to 
determine utility in a variety of soft tissue engineering applications, we determined the 
strength of collagen matrices as a function of alignment. Collagen gels of various 
concentrations from 0.3125 mg/mL - 2.5 mg/mL we aligned, dried and crosslinked with 
genepin. Uniaxial stress-strain testing collagen lamellae were performed using a DMTA 
V mechanical tester. Rectangular strips, 20 mm x 5 mm were cut from sheets of 
unaligned and aligned matrices in the direction of alignment, and perpendicular to 
alignment. Sheets were mounted vertically on the testing platform and immersed in PBS 
at 37°C. Samples were preconditioned and tested to failure. Samples that failed at the 
mounting points and those that slipped were discounted from analyses. Mechanical 
anisotropy was noted correlating to structural anisotropy. The mechanical strength, 
ultimate tensile strength (UTS), and stiffness, Young’s modulus (Mod.), of aligned 
collagen matrices were significantly higher than that of unaligned samples, irrespective of 
concentration, Table 2.1. Aligned matrices showed an approximate doubling in 
mechanical strength independent of concentration, for 2.5 mg/mL gels from ~3.50 MPa 
to 8.00 MPa, Table 2.1. Further, stiffening of matrices occurred, resulting in Young’s 
Moduli increases for 2.5 mg/mL gels from 38.7 MPa to 103 MPa, Table 2.1. Mechanical 
strength was a function of alignment with 10% aligned matrices having significantly 
lower UTS and Young’s Moduli than 20% aligned matrices, Figures 2.5 A & C, Table 
2.1. The mechanical strength in the direction perpendicular to that of alignment in 
anisotropic samples was not significantly different than unaligned samples, Figure 2.5. 
Increase in stretch amount of 2.5 mg/mL matrices from 10% to 20% resulted in a greater 
amount of alignment, and consequently in significantly higher strength and stiffness 
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(p<0.05), Table 2.1. Further, this correlated with maximum relative frequency of fibrils, 
which was significantly different for unaligned, 10% aligned and 20% aligned matrices, 
although the distribution of fibrils from the peak, FWHM, was not, Table 2.1. Strain to 
failure of collagen matrices did not change significantly as a function of alignment, 
Figure 2.5 B. Collagen matrices did not show a significant difference in fibril diameter as 
concentration or alignment varied, ranging from 74.3 ± 11.4 nm to 88.5 ± 11.7 nm, Table 
2.1. Further, concentration of initial gels did not significantly affect dried lamella 
thickness, Figures 2.5 D & E and Table 2.1. We have thus demonstrated the ability to 
modulate mechanical strength as a function of strain amount and strain rate. Further, 
microstructural alignment of collagen fibrils provides structural and mechanical 




Figure 2.6: Representative stress-strain plot of collagen matrices. Matrices were 
stretch-aligned to different amounts at a rate of 3 µm/s (: 20%,… : 10%, ---:0%). 
Samples were cut into 20 mm long x 5 mm wide strips and mechanically tested. Samples 





Table 2.1: Consolidated mechanical and structural properties of collagen lamellae cast at different initial 






















0.3125 88.4 ± 12.5 26.4 ± 1.42 
3.71 ± 
0.716 10.0 ± 1.19 
43.1 ± 
7.80 NA NA 0 
0.625 74.3 ± 11.4 27.6 ± 1.04 3.25 ± 0.31 10.5 ± 1.25 
44.7 ± 
8.21 NA NA 0 
1.25 75.7 ± 14.8 28.5 ± 2.68 
3.27 ± 
0.400 11.2 ± 1.60 
42.7 ± 
3.51 NA NA 0 
2.5 83.1 ± 9.44 26.7 ± 2.58 
3.50 ± 
0.478 10.4 ± 1.73 
38.7 ± 
9.37 NA NA 0 
0.3125 88.5 ± 11.7 24.9 ± 2.03 
7.57 ± 







0.625 85.4 ± 12.2 25.7 ± 2.06 
7.43 ± 







1.25 83.4 ± 9.26 26.3 ± 1.86 
7.49 ± 

























Collagen based fabrics can be aligned by stretching to generate structural and 
mechanical anisotropy. Collagen gels are generated by the neutralization of acidified 
Type I monomeric rat tail tendon collagen in a phosphate based buffer. Gel dimensions 
are dependent on the volume of collagen solution and buffer used, and allow for large 
(centimeter scale) structures to be fabricated. Fibrillogenesis within gels is further 
enhanced by incubation in a fiber incubation buffer. Gels are subsequently dried to less 
than 1% of their original thickness to create high density collagen mats, 4 mm cast gel 
dried to 28 µm. Structural anisotropy was generated by adhering gels onto mechanical 
supports and stretching at rates of 3 µm/s and 300 µm/s to strains of 10% and 20%. 
Previous reports of gelation systems and fabrication of smaller-scale anisotropic collagen 
matrices have been limited in size (sub-micron to millimeter scale) which have shown 
lack of scalability or utility for regeneration of large tissue replacements [187]. 
 
Dependence of gelation conditions on ultrastructure of collagen gels. Collagen 
gelation kinetics is highly dependent on collagen isolation method, initial collagen 
concentration, temperature of gelation, pH and presence of ions. Several groups have 
shown the effects of the aforementioned parameters on fibrillar size and 
microarchitecture of collagen matrices [203; 204; 205; 206; 207; 208]. Pepsin digested 
collagen structures are devoid of telopeptide sequences that are critical to fibril formation 
with recapitulation of native collagen D-periodic structure, unlike acid solubilized 
collagen which still retains telopeptide sequences.  The literature is replete with 
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conflicting reports on fibril diameter and parameters that influence gelation. Reports have 
noted the effect of longer gelation times, and lower initial concentrations of collagen 
allow more time for fibrillogenesis without spatial restrictions from adjacent fibrils; our 
studies indicate little difference in fibril diameter as a function of concentration (0.3125 
mg/mL – 2.5 mg/mL) in our gelation conditions, buffers used, stretch rate or stretch 
amount, Table 2.1 [209; 210; 211; 212; 213; 214]. These small nanoscale differences do 
not directly translate to larger scale mechanical differences in ultimate tensile strength or 
strain at failure of centimeter scale constructs. Rather, there is a dependence on 
processing conditions and architectural arrangement of collagen fibrils in terms of 
alignment and packing density [184; 185; 215; 216; 217]. Further the importance of D-
periodicity is exemplified by the characteristic 67 nm banding pattern of collagen (Figure 
2.2 C-D), which helps maintain the native structure of the collagen; this is critical in 
higher order architectures that involve fibrillar collagen formation and preservation of 
cell binding moieties (ex. GFOGER which mediates binding with cell surface integrins). 
Further, integrin-mediated binding to collagen is dependent, on 3 dimensional structural 
motifs that are generated by the triple helix, and is dependent on the denaturation state of 
collagen [218; 219; 220]. 
 
Modulation of mechanical properties of collagen gels. Generation of structural 
anisotropy within fiber matrices has been known to significantly improve their strength. 
Specific to collagen, our group and others have shown that anisotropic collagen structures 
can withstand greater mechanical load bearing applied in the direction of fibrils [185; 
188; 201]. Stretching of collagen gels has been shown not only to yield structural 
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anisotropy and linear alignment of collagen fibrils in the direction of applied strain, 
Figure 2.3, but also mechanical strengthening and reinforcement, Table 2.1 and Figure 
2.4. Although of significant strength, uncrosslinked collagen constructs may degrade 
more quickly and are of lower strength than crosslinked constructs [217]. Therefore, we 
chose to employ a crosslinking scheme to strengthen our collagen matrices and modulate 
potential degradation. Genipin, a naturally occurring crosslinker, known specifically for 
its ability to conjugate lysine residues and impart significant strength onto bioengineered 
matrices, has also been established to be biocompatible [221; 222; 223]. Genipin 
crosslinked matrices exhibit an increase in ultimate tensile strength and stiffness, 
Young’s modulus, with little to no change in strain at failure. Ultimately, uncrosslinked 
and crosslinked collagen constructs allow for the generation of a variety of mechanically 
tunable structures which can be adapted to several tissue engineering applications, 
including the development of blood vessels, cartilage, tendon, abdominal wall defect 
replacements or artificial skin, to name a few.   
 
Dissimilitude and advantages compared to alternative alignment techniques. The 
importance of alignment and structural anisotropy in tissue engineered constructs is 
critical to recapitulation of native tissue mechano-biological behavior. Several groups 
have attempted to align collagen matrices that have resulted in monolayers of aligned 
collagen, matrices of varying collagen densities, thin collagen gels, weak matrices unable 
to support physiologically relevant loads and matrices with isolated regional alignment. 
The methods of these attempts include electrical gradients,[199] magnetic fields,[188; 
189] microfluidics,[187; 198; 224] patterned substrates[113; 225] and mechanical 
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stresses [201].  Cheng et al used an electric field to align collagen molecules into a thick 
strand, 50-400 µm.  However, their technique destroys the native collagen structure and 
denatures the molecule, as demonstrated by the lack of D-periodicity in their collagen 
fibers [199].  The use of large scale magnetic fields, 1-10 Tesla, to orient diamagnetic 
collagen molecules is prohibitive in cost, safety and efficiency in the rapid generation of 
collagen matrices, as described by Torbet and Ronziere[189] and Tranquillo’s group 
[194; 195; 196; 197].  Although Cheng and Kaufman have described a methodology 
wherein magnetic beads with modified surface functionalities help align collagen 
molecules in a weaker magnetic field (10-4T), the gels made were an order of magnitude 
smaller than in this study, and included a proxy material that could potentially be 
deleterious depending on the application of the material [187].  Lee et al and Lanfer et al 
have employed the use of microfluidics to align collagen molecules [198; 224; 226; 227].  
In addition to the significantly thinner and small constructs that they have synthesized, 
the potential for the formation of a density gradients across the sample due to viscous 
flow shear lamellae, and along the sample due to fibril polymerization prior to fully 
traversing the length of the channel, can create inhomogeneities within samples.  Further 
removal of aligned collagen constructs from channels restricts these methods to much 
smaller scales, unsuitable for large scale tissue engineering.  Moreover, their studies 
require longer processing times and layer-by-layer deposition of multiple aligned 
collagen matrices in order to gain utility.  This study however employs large (10 x 8 cm) 
collagen gels with gel thicknesses of 4 mm.  Further, these constructs are freely moving, 
unadhered to a surface and can be easily manipulated into larger tissue based constructs.  
Deitch et al have employed inkjet printer technology to print collagen solutions onto 
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glass substrates.  The thin films they have produced lack consistency and have not 
demonstrated precise molecular alignment [200].  Vader et al have used a similar 
technique of strain alignment for the formation of structural anisotropy with collagen 
gels.  Their study used controlled actuation of glass rods which perforated small 1 mm 
thick collagen gels.  The imposed strain between the glass rods yielded localized regions 
of alignment within the sample.  They reported plastically deforming uncrosslinked gels 
into aligned states, but noted that glutaraldehyde crosslinked gels were structurally elastic 
[201]. Although an elegant strategy, their alignment technique lacked versatility and 
scalability – localized regions of alignment, small size of the collagen gels, and low 
mechanical strength. Herein we have described a novel technique to create large 
constructs with global tunable alignment and a strategy for the development of high-






Collagen is a critical building block of the extracellular matrix.  The present study has 
demonstrated the ability to generate large collagen matrices with suitable mechanical and 
structural properties to native tissue structures with preservation of native fibrillar 
structure and characteristic D-periodicity.  Further we have circumvented the problem of 
weakness in collagen gels, which are usually too weak to be used in many tissue 
engineering applications, by drying and crosslinking them into high density lamellae that 
have mechanical strengths on the order of several soft tissues, 1-10MPa.  Further, large 
lamellae can be fabricated with structural anisotropy.  The amount of collagen fibril 
alignment is dependent on the amount of strain induced on the matrix and on the 
stretching rate, with a maximum alignment of 6.86%, with greater than 95% of fibrils 
within ±35.2˚ of the direction of alignment.  The utility of this fabrication scheme allows 
for the rapid fabrication of large, aligned collagen matrices which can be further 
investigated for use to mimic native tissue structures. 
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CHAPTER 3 




The generation of scalable mechanically matching and biocompatible materials 
comprising completely natural biopolymers for soft tissue engineering has been a 
challenge the biomaterials field has been attempting to address for over a half century 
[228]. Coupled with the immense cost of disease specific morbidity and mortality, many 
efforts, and multi-billion dollar federal funding, have been devoted to the development 
and fabrication of tissue-mimetic constructs [229]. However, most materials have been 
fabricated for only one or a few tissue specific applications. Additionally, significant 
efforts have been made to engineer in vitro living tissue systems and organs; however, 
most of these approaches have utilized weak synthetic hydrogels that lack mechanical 
strength for ultimate in vivo utility given their poor mechanical strength, cell adhesive 
properties, and the lack of a native extracellular matrix environment to physically and 
biologically recapitulate native tissue growth/responses. 
 
Several groups have attempted to use synthetic non-degradable and biodegradable 
polymers to recapitulate the ECM environment by generating nanofibrous architectures. 
Common techniques include porogen leaching [230], gas foaming [231], freeze drying 
[232], electrospinning,[233] 3D printing, sterolithography, solid free form fabrication and 
a variety of other technologies summarized well by Sachlos and Czernuszka [234]. While 
 52 
these techniques have shown reasonable promise, concerns over immune rejection, 
macrophage/neutrophil mediated degradation, inflammation, mechanical failure, and 
ultimately integration into the host system have limited large-scale utilization. 
 
Another widely studied alternative to the generation of ECM-mimetic scaffolds is the 
decellularization of native tissue matrices. After devitalization and removal of potentially 
immunogenic antigens, tissues are often crosslinked to maintain stability and mechanical 
integrity. Further, the complex 3D structure of tissue is retained in decellularized 
scaffolds; this in turn aids the infiltration of scaffolds and presents a conducive niche for 
regeneration. The resulting scaffolds have found many uses in the engineering of a 
variety of tissue replacements [235; 236; 237]. However, decellularized matrices lack 
defined architecture and can often become irreversibly damaged during processing. 
Consequently, there is a diminished ability to mechanically tune such matrices without 
the addition of dopants, which may in turn elicit a host tissue response. Further, given 
that most decellularized tissues are harvested from xenogenic sources, there is the 
potential for residual xeno-antigen presentation and residual cells/ cell fragments, which 
may result in an immune response, even if the ultimate building blocks of the scaffold 
(collagen, elastin, proteoglycans) have high interspecies homology. Conversely, 
allogeneic matrices may lack availability and harbor a potential for viral or bacterial 
transmission. Thus, there exists a large demand for the generation of engineered matrices 
that provide a 3D niche for tissue infiltration and integration, which can be mechanically 




Noting these considerations, we have identified 5 critical criteria for tissue engineered 
scaffolds: (1) require minimal processing and allow for scalable manufacture, (2) have a 
hierarchical structure that can be tailored both structurally and mechanically to match 
native tissue, (3) provide a conducive environment for cellular adhesion, growth and 
proliferation, (4) degrade to yield non-toxic products, and (5) cause minimal 
inflammatory response. Capitalizing on the natural abundance of collagen in native 
tissues, we have designed a bottom-up approach for the creation of bioartificial matrices. 
Coupled with a recently described recombinant elastin-like protein polymer (ELP) [238; 
239], we have generated collagen fiber-elastin reinforced nanocomposites for utility in 
soft tissue applications.  To mimic the crimped form of fibrous collagen which supports 
tensile loading in native tissue (10 – 200 µm wavelengths) [240; 241], we have applied 
excimer laser ablation to create “wavy” collagen structures that enhance tissue 
engineered matrix compliance (<10 – 90 % elongation at break) with no appreciable 
protein denaturation.  By systematically controlling collagen gel hydration and global 
micro- and macro- structure, a series of strong (1-15 MPa strength) collagen sheets 
embedded with elastin have been developed with mechanical and biological properties 
that mimic native tissue. Cytocompatibility was established by culture of bone marrow 
derived mesenchymal stem cells, showing confluence within hours and conformal 
scaffold based cell morphology. Through the development and utilization of layer-
reinforced collagen networks and novel microfabrication techniques, we have developed 
a natural biopolymer matrix with tunable mechanical properties that have potential for 
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use as biosynthetic blood vessels, tendon replacements, hernia patches, muscle tissue, 
nerve guidance conduits, artificial skin and other soft tissue applications. 
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3.2 Materials and Methods: 
 
All chemicals were purchased from Sigma-Aldrich, unless otherwise stated. 
 
Isolation and purification of monomeric collagen. Monomeric Type I rat tail tendon 
collagen was obtained by acid extraction from Sprague-Dawley rats (Pel-Freez 
Biologicals, Rogers, AR) following a procedure adapted from Silver and Trelstad [202].  
Briefly, rat tail tendons were extracted with the aid of autoclaved pliers and dissolved in 
10 mM HCl for 4  h at 25°C to dissolve the proteinaceous components.  Insoluble tissue 
and other contaminants were removed by centrifugation at 30,000g at 4˚C for 30 mins 
with subsequent vacuum filtration through 20 µm, 0.45 µm and 0.2 µm filters.  The 
sterile filtered collagen in HCl was precipitated from solution by adding NaCl to a final 
concentration of 0.7 M.  The precipitated collagen was pelleted by centrifugation, 
redissolved in 10 mM HCl and dialyzed first against 20 mM phosphate buffer at room 
temperature, then at 4°C, second against 10 mM HCl at 4°C and finally against deionized 
water at 4°C.  The collagen was then frozen and lyophilized till use. 
 
Production of collagen mats. Monomeric rat tail tendon collagen dissolved in 10mM 
HCl, at concentrations of 0.3125 mg/mL-2.5 mg/mL, was neutralized using a gelation 
buffer (4.14 mg/mL monobasic sodium phosphate,12.1 mg/mL dibasic sodium 
phosphate, 6.86 mg/mL TES (N-tris (hydroxymethyl) methyl-2-aminoethane sulfonic 
acid sodium salt, 7.89 mg/mL sodium chloride, pH 8.0) at 4˚C, in rectangular molds (10 x 
8 cm) for 24 h.  Gel thicknesses were 2, 3, or 4 mm. Gels were subsequently placed in a 
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fiber incubation buffer (7.89 mg/mL sodium chloride, 4.26 mg/mL dibasic sodium 
phosphate,10 mM Tris, pH 7.4) at 37°C for 48 h to promote fibrillogenesis [203].  Gels 
were then dried at room temperature under a steady air stream to create collagen mats. 
Stacked lamellae consisting of 2 to 8 layers were generated by serially drying additional 
gels on top of dried mats.  Some specimens were crosslinked in genipin at 6 mg/mL in 1x 
PBS at 37°C for 24 h. 
  
Excimer ablation of collagen mats. Two different mask types were used in this study: 
stainless steel masks and quartz masks. Stainless steel masks were constructed by 
infrared laser ablation of 50 µm thick stainless steel sheet stock. Quartz contact masks 
(Advance Reproductions, MA) were fabricated using photolithography and wet etching 
of 5 µm thick aluminum coated quartz. Five designs consisting of linear or sawtooth 
ablation patterns were investigated with geometric design variables consisting of strip 
length, strip width, interstrip gap and vertical strip width. These variables ultimately 
dictated the frequency and amplitude of the resultant waveform, Figure 3.2. The mask 
was placed over collagen matrices and ablated with an excimer laser with parameters 
adjusted to yield a fluence of 26.7 J/cm2 (Microelectronics Research Center at Georgia 
Tech, Atlanta, GA).  
 
Microdifferential scanning calorimetry of collagen mats. To determine the effect of 
lamella fabrication and excimer laser ablation on collagen triple helical structure, thermal 
denaturation temperature and enthalpy of denaturation were measured using a differential 
scanning calorimeter (µDSC, SETARAM, Pleasanton, CA). Briefly, 5-10 mg segments 
 57 
of lyophilized collagen, dried collagen lamellae pre or post excimer ablation, and post 
crosslinking in genipin were hydrated in 0.5 mL of PBS for 10 h at 5˚C. Lamellae were 
then heated from 5°C to 90°C and back to 5°C at 0.5°C/min. The enthalpy of phase 
changes relating to denaturation, HD, was measured, as well as the denaturation 
temperature, TD. Complete denaturation was confirmed by the lack of a denaturation peak 
upon a repeated heating (to 90°C) and cooling cycle.  
 
Synthesis of a recombinant elastin-like protein polymer (ELP). Development and 
production of the ELP, LysB10, has been described elsewhere [239]. Briefly, a triblock 
amphiphilic copolymer was designed to contain hydrophobic endblocks and a hydrophilic 
midblock.  The 75kDa polypeptide comprised 33 repeats of the pentapeptide sequence 
[IPAVG]5, and the 58 kDa midblock comprised 28 repeats of the sequence 
[(VPGAG)2VPGEG(VPGAG)2].  Flanking both the hydrophobic plastic endblocks and 
the hydrophilic elastic midblock were the crosslinkable amino acid sequences: [KAAK] 
which allow for amine-based crosslinking. Subsequent to expression in E. coli protein 
was extracted and purified using hot/cold centrifugation cycles and nucleic acid removal. 
Protein solutions were then dialyzed against water and lyophilized. 
 
Fabrication of planar nanofibrous collagen-elastin composites. LysB10, dissolved in 
molecular grade water (10 mg/mL, 4˚C) was used to embed single layer and multi-layer 
collagen lamellae in a sandwich molding setup.  The setup was warmed to 25˚C to allow 
the LysB10 solution to gel, creating single ply composites. Single ply were stacked, 
cooled and reheated to create multi-ply structures [242]. 
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Imaging of composite architecture. Optical microscopy, fluorescence microscopy, 
scanning electron microscopy (SEM), and transmission electron microscopy (TEM) were 
used to analyze the collagen structure pre and post embedment in elastin. For SEM 
studies, briefly, dry collagen lamellae were hydrated in water for 24 h and dehydrated in 
serial exchanges of ethanol-water mixtures from 30%-100%.  The samples were then 
critical point dried (Auto Samdri 815 Series A, Tousimis, Rockville, MD), sputter coated 
with 8nm of gold (208HR Cressington, Watford, England)  and imaged at an accelerating 
voltage of 10keV using a field emission scanning electron microscope (Zeiss Supra 55 
FE-SEM, Peabody, MA). To determine the ultrastructure and presence of D-periodicity 
in the fibrils, showing maintenance of native collagen structure, hydrated samples were 
prepared for TEM.  Samples in PBS were washed in 0.1M cacodylate buffer and fixed in 
glutaraldehyde.  After washing in water, samples were partially dehydrated in ethanol and 
stained with uranyl acetate.  Samples were then fully dehydrated in ethanol, embedded in 
resin and polymerized.  Ultrathin (60 - 80 nm) were cut using a RMC MT-7000 
ultramicrotome (Boeckeler, Tucson, AZ).  Post-staining with uranyl acetate and lead 
citrate was followed by imaging using a JOEL JEM-1400 TEM (JOEL, Tokyo, Japan) at 
90 kV.  
 
Rat mesenchymal stem cell (rMSC) cell culture. Bone marrow-derived rMSCs (Stice 
lab, University of Georgia, GA) were seeded onto collagen constructs to establish 
cytocompatibility.  Collagen scaffolds with and without microablation were sterilized in 
70% ethanol for 30 min, washed several times in 1X PBS, and incubated in media for 30 
 59 
min prior to cell seeding. Cells were cultured in Alpha MEM, supplemented with 10% 
fetal bovine serum, 1% L-glutamine and 1% penicillin-streptomycin. Cells were removed 
from tissue culture-treated polystyrene flasks using 0.25% trypsin-EDTA, suspended in 
media, and seeded at a concentrations of 100 000 cells/cm2 for 24 h.  
 
Assessment of cellular viability and alignment. Cell adhesion and morphology was 
probed using Live/Dead staining (Invitrogen, Carlsbad, CA), and Alexa Fluor® 568 
phalloidin (Invitrogen, Carlsbad, CA), as per manufacturer’s protocol. For Live/Dead 
staining, scaffolds were washed 3 times in PBS without divalent salts, and incubated with 
2 mL of Live/Dead stain (2µM calcein AM and 4µM Ethidium homodimer-1 solution in 
PBS) for 1 hour. Scaffolds were then placed on glass slides with the addition of 20µL of 
Live/Dead stain and coverslipped. Stained cells were imaged using a Lecia SP5 confocal 
coupled with a white light laser and adjustable emission collectors (Leica, Buffalo Grove, 
IL). Calcein AM was imaged using excitation of 488 nm and emission of 518 nm, and 
Ethidium homodimer-1 was imaged at an excitation of 528 nm and emission of 617 nm. 
For cellular alignment, actin filament organization was probed. Briefly, scaffolds were 
washed with PBS, fixed in 4% buffered paraformaldehyde, washed in 0.5% Triton X in 
PBS, washed in 100mM glycine in PBS, blocked with 1% BSA in PBS, and stained with 
Alexa Fluor 568 phalloidin dissolved in methanol. Excess stain was washed in PBS. 
Scaffolds were mounted onto glass slides, 20 µL of DAPI Prolong Gold® (Invitrogen, 
Carlsbad, CA) was added and coverslipped. Scaffolds were imaged after 24 h using a 
Leica SP5XMP inverted confocal microscope (Leica, Buffalo Grove, IL) coupled with a 
white light laser and 405 nm diode laser. DAPI was imaged using excitation of 405 nm 
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and emission of 461 nm, and phalloidin was imaged using excitation of 578 nm and 
emission of 600 nm. 
 
Mechanical testing of composites. To simulate application in planar soft tissues, 
collagen sheets (with and without microablation) were cut into 20mm x 5mm strips and 
mounted onto a Dynamic Mechanical Thermal Analyzer V (DMTA V, Rheometric 
Scientific, Piscataway, NJ) with a gauge length of 10mm, immersed in PBS at 37˚C. 
Samples were preconditioned 15 times to 66% of the average maximum failure strain 
determined from pilot samples, and then tested to failure at 5 mm/min (n=8 for each 
group).  Hydrated thickness was measured using optical microscopy for calculation of 
cross-sectional area.  Young’s modulus was determined from the slope of the last 4% of 
the stress-strain curve. Suture retention strength of planar constructs was determined by 
cutting 4mm x 4mm square inserting 4-0 FS-2 prolene suture (Ethicon) through the 
center of the segment, and pulling out the suture with force measured on the DMTA (n=4 
for each design). 
 
Statistical Analysis. Means and S.D. was obtained for all measurements, image analyses 
and mechanical data.  Comparisons will be made using the Student’s t test for paired 
data, ANOVA for multiple comparisons, and Tukey post hoc analysis for parametric 
data.  Nonparametric tests were carried out using the Kruskal-Wallis ANOVA, with 






Generation of collagen lamellae and nanofibrous composites. Collagen materials with 
high strength and tunable mechanical properties were generated in single and multiple 
layers, Figure 3.1.  Multi-layer mats, generated by the serial drying process, were well-
integrated with no distinguishable interface between layers. Mechanical peeling of 
lamellae resulted in whole tears, without the ability to tweeze out individual layers of 
multi-layer mats. 
 
Collagen mats, due to their fibrillar nature, allow for impregnation with alternative 
matrices that can modulate mechanical or biological behavior. The sandwich molding 
technique permited the infusion of ELP into collagen matrices, leading to nanofibrous 
composite matrices, schematically shown in Figures 3.1 B, C, E, & F [182; 183; 242]. 
Dry matrices before and after the addition of ELP had spatial densities of 0.772 ± 0.0626 
mg/cm2 or 0.983 ± 0.0558 mg/cm2, respectively, suggesting the composite matrices are 
78.5% collagen and 21.5% ELP by dry weight. In addition to the single- and multi-layer 
lamellae described above, the ELP molding process allowed the formation of single- and 




Figure 3.1: Schematic of fabrication strategy for layered collagen elastin 
nanocomposites. Collagen gels were cast at 4mm thickness. (A) Collagen lamellae are 
dried to a dry thickness of approximately 10 µm, (D) and layered into multi-layer 
collagen mats. (B) Single layer collagen lamellae are embedded in elastin into a single 
ply, in a sandwich molding technique, (E) multi-layer lamellae are embedded into a 
multi-layer single ply composite. (C) single layer single ply composites are stacked into 
single layer multi-ply composites, (F) multi-layer single ply composites are stacked into 
multi-layer multi-ply composites. 
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Mechanically tunable collagen lamellae as a function of concentration, thickness and 
layering. Initial collagen constructs showed a significant increase in strength and 
stiffness of matrices as a function of concentration, but not a significant difference in 
strain at failure, Figures 3.2 A, B & G.  When compared to single layer matrices, multi-
layer matrices showed an increase in strength (4-14 MPa), strain at failure (10-17 %) and 
stiffness (40-100 MPa), Figure 3.2 C, D & I. Increasing gel thickness from 2 to 4 mm 
prior to drying resulted in collagen lamellae of increasing strength and stiffness, with no 
significant effect on strain-at-failure, Figures 3.2 E, F & K. Individual collagen lamellae 
had a nominal thickness of 14.9 - 40.8 µm depending on initial collagen concentration in 
the gels, Figure 3.2 H. Layering of collagen gels showed a commensurate near-linear 




Figure 3.2: Mechanical properties of genipin crosslinked collagen mats. Increasing concentration of initial gels results in improved 
strength and stiffness with a commensurate increase in thickness (A,B,G,H). Increasing the number of layers shows an increase in 
strength and stiffness (C,D,I,J). Increasing initial thickness of 2.5 mg/mL collagen gels in 4 layer lamellae systems resulted in 




Development of structurally and mechanically anisotropic collagen 
microarchitectures. Excimer laser ablation permits the use of a variety of masking 
techniques to ablate almost any design onto collagen substrates. Critical features of the 
triangular waves designs, described herein, included wave height, strip width, inter-strip 
width, wave width, and vertical strip width, Figure 3.3 A and Table 3.2. The fidelity and 
resolution of the excimer laser allows for exact cuts to be made into the collagen mats, 
Figure 3.3 B, C, D. Although the theoretical resolution of the excimer laser is 248 nm, the 
practical resolution is typically higher. Consequently minimum feature sizes were 10 µm, 
Table 3.2. 
 
Preservation of collagen macromolecular structure. Thermal analysis showed that the 
denaturation temperature of lyophilized collagen was lower than uncrosslinked and 
crosslinked collagen mats, 46.0 ± 0.5°C, 52.9 ± 0.4°C and 73.2 ± 2.1°C, respectively, 
Table 3.1. Lyophilized collagen consisted of monomeric collagen prior to higher order 
assembly, thus exhibiting a lower TD than collagen mats, which were treated with 
phosphate buffer. Further the ion concentrations, pH and heating rate (in addition to 
buffer type) contribute to collagen monomer organization into larger fibrils. Additionally, 
changes in ultrastructure conferred during phosphate buffer treatment and densification of 
the matrix during lamella fabrication contribute to a higher TD for collagen mats. 
Lyophilized collagen and collagen lamellae exhibited similar HD. Crosslinking of 
matrices results in a greater stabilization of the collagen structure and consequently raises 
the TD, but lowers HD. There was no significant difference in the thermal transitions or 
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enthalpy between collagen lamellae with and without ablation, Figure 3.4 and Table 3.1, 
suggesting no measurable loss in triple helical structure.  
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Figure 3.3: Ablation schemes of collagen matrices. (A) Schematic of collagen lamella 
ablated using an excimer laser to create a defined “wavy” collagen lamella with linear 
supports, inset shows additional nomenclature. (B) Uniformity and transfer of wavy 
ablated pattern with high fidelity onto collagen mats, scale bar 500 µm. (C-D) Ablated 
collagen lamella displayed clear excimer laser cuts with no apparent material damage, 




Figure 3.4: Endothermic heat transitions of collagen matrices. Microdifferential 
scanning calorimetry of lyophilized collagen (solid), collagen lamella (dotted), excimer 























±0.396 53.1±0.203 73.2±2.11 
∆H 




Monomeric rat tail tendon collagen (MRTC), lyophilized collagen (Col. lyophilized), collagen lamella (Col. mat), collagen lamella 
excimer ablated (Col. lamella excimer), collagen lamella crosslinked in 6 mg/mL genipin, 37°C, 24 h (Col. lamella X-link). *[185] 
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Design of mechanically variant structures for optimized mechanical compliance. 
Pilot designs ablated into collagen lamellae to show proof of principle and to benchmark 
ablation techniques involved ablation of holes 10-100 µm in diameter, direct write of 
lines and waves, and variations of the designs listed in Table 3.2. However, it was 
realized that the strip width to height (film thickness) ratio needs to be approximately < 1 
to ensure features are stable and do not laterally collapse during subsequent processing. 
Further, it was determined that thick wave strips (> 180 µm) resulted in out of plane 
bending of wave features, data not shown. Consequently, the subset of designs that 
resulted in improvements of mechanical properties is shown, Table 3.1. Linear ablation 
patterns were also generated to determine the altered mechanical response as a function 
of excimer laser ablation pattern. Wave patterns with varied vertical strip thickness 60-
600 µm and interstrip thickness with variation from 10-30 µm demonstrate the 















wave crest (˚)  
Strip aspect ratio 
(Height : Width) 
Vertical Strip 
thickness (µm) 
1 2000 120 10 0 0.5 100 
2 500 60 30 60 1 60 
3 500 60 10 60 1 100 
4 500 60 10 60 1 300 





Figure 3.5: Meso- and ultra-structure of collagen matrices of varying vertical strip width. (A-E) Optical micrographs of stainless 
steel (B) and aluminum-on-quartz masks (A, C, D, E) for Designs 1-5 (A-E), respectively, scale bar 500 µm. (F-J) Optical 
micrographs of genipin crosslinked collagen lamellae for Designs 1-5, respectively, scale bar 500 µm. SEM of wavy collagen matrices 
(K) 200 X, wave edge (L) 5 kX, and magnified view of fibrillar structure (M) 50 kX, scale bars 300 µm, 10 µm, 1 µm respectively. 




Collagen lamella ablation closely mimics mask features with no protein 
denaturation. Metal masks (stainless steel shim stock, 50 µm), Figure 3.5 B, or 
aluminum coated quartz, Figures 3.5 A, C-E, allow laser transmission through 10-30 µm 
gaps, showing high ablation fidelity, allowing patterns on the centimeter scale to be 
completely ablated over a period of less than 1 h, Table 3.2 and Figures A-E and F-J. 
Collagen wave ablation shows high precision and uniformity under SEM, Figure 3.5 K, 
which is composed of a nanofibrous (80µm) fibrillar matrix, Figure 3.5 L & M. To 
demonstrate regeneration and reconstitution of native collagen structure, in addition to 
the differential scanning calorimetry described above, native collagen banding structure 




Figure 3.6: Mechanical strength of ablated collagen mats, Designs 1-5. (A) Ultimate tensile strength of ablated crosslinked 




Mechanical properties of ablated composites. The utility of excimer laser ablation to 
modulate stiffness and extensibility is shown, Figure 3.6. Linear ablation patterns result 
in a slightly greater than 50% reduction in tensile strength from unablated matrices, 5.82 
± 0.93 MPa vs 13.3 ± 2.19 MPa, Figure 3.2 C vs Figure 3.6 A. In the triangular wave 
designs, increasing vertical strip width enhanced ultimate tensile strength. With other 
features constant, vertical strip width ranging from 100 µm, 300 µm and 600 µm (designs 
3-5), had UTS of 0.958 ± 0.172 MPa, 1.20 ± 0.296 MPa, 1.43 ± 0.162 MPa, respectively. 
This trend is maintained with collagen waves in Design 2 which had a significantly lower 
UTS of 0.683 ± 0.168 MPa, a thinner vertical strip thickness, 60 µm, and waves spaced 
further apart, 30 µm. Triangular patterning tended to increase strain at failure, from 9.43 
± 1.76 % for linear ablation patterns (Design 1) to 44.5 ± 8.27 %, 51.8 ± 14.4 %, 65.9 ± 
8.19%, and 69.6 ± 10.9 % for Designs 2-5, respectively.  Further, there is a significant 
increase in the strain at failure for Designs 4 and 5 over Design 2. The Young’s modulus 
of linear ablated constructs is significantly higher than that of triangular wave patterned 
collagen, 88.1 ± 12.9 MPa, compared to 3.95 ± 0.839 MPa, 2.92± 0.579 MPa, 5.24 ± 1.00 
MPa, 5.06 ± 1.34 MPa for Designs 2-5, respectively. Suture retention strengths for 4 
layer composites, stacked into 4 ply systems with ELP, showed a suture retention 
strength of 52.4 ± 9.18 gF. However, ablated constructs, which have less collagen, had 
suture retention strengths of 51.2 ± 7.43 gF, 37.7 ± 12.1 gF, 40.1 ± 5.88 gF, 36.36 ± 6.23 






Figure 3.7: Cellularization of unablated and ablated scaffolds. (A)Unablated scaffold seeded with rMSCs at 100,000 cells/cm2, for 
24 h Live (green)/Dead(red) stained. (B) Ablated scaffold seeded with rMSCs at 100,000 cells/cm2, for 24 h (Design 2). (C) Actin 




Structural features dictate cellular adhesion. Adhesion and spreading of rMSCs on 
microablated collagen matrices was observed within 4 h and proliferation in 24 h, Figure 
3.7 A, at low seeding densities, 100,000 cells/cm2. Further through the use of 
microfabrication techniques, we have established a novel method to enhance adhesion 
and conforming of cells discretely to microablated matrices, as seen in Live/Dead 




Use of purified collagen and recombinantly expressed elastin to mimic the 
extracellular matrix. The extracellular matrix is composed of several components that 
provide strength (collagen, mineral phosphates), structural support and anisotropy 
(collagen, elastin and proteoglycans), and cell adhesion (collagen, glycoproteins, 
fibronectin, laminin). Recapitulation of the nanofibrous ECM milieu has been attempted 
using a variety of technologies – electrospinning,[243; 244] nanofibrous scaffolds[245] 
and use of biological (naturally derived/ reconstituted) matrices [246]. However several 
drawbacks limit the use of synthetic materials – immuno-rejection, degradation products, 
denaturation of electrospun protein based polymers, and lack of tunability of mechanical 
properties to match that of native tissue. The choice of collagen as a biomaterial is 
supported by the fact that it naturally forms a fibrillar nanofibrous structure, is naturally 
capable of cell adhesion, has high species homology, and is FDA approved for several 
collagen based products. However to date one of the primary limitations of collagen 
based tissue engineering is the inability to modulate the mechanics, strength, and 
suturability of relatively weak collagen scaffolds.  
 
Noting the abundance and importance of collagen, we have developed a facile method for 
the production of cell adhesive matrices that can be generated with structural anisotropy 
while maintaining modulatable tissue-like strength. For applications in soft tissue 
engineering, the stiffness and compliance of matrices is of critical importance. Further, 
the ability to modulate these features allows for the generation of a class of novel 
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biopolymers that can architecturally and physiologically replicate native tissue. Collagen 
matrices currently used in tissue engineering have primarily been in hydrogel form which 
are often weak and lack clinical utility in mechanically demanding applications. Further, 
hydrogels have the potential to collapse by elimination of water, shrink by degradation or 
cell-matrix interactions, and fail due to repeated mechanical conditioning. To obviate 
these limitations, we have developed and characterized a novel fabrication strategy that 
harnesses the cell adhesive properties of collagen matrices, coupled with drying 
techniques that enhance the structural strength and novel laser ablation technology to 
generate structural anisotropy. 
 
Collagen matrices neutralized from acid solutions of collagen created gels. 
Fibrillogenesis was enhanced through the use of fibril incubation buffer. Resultant gels 
were dried to less than 1% of their initial thickness. With the ability to create gels of any 
size, we have fabricated large-scale constructs that can be used for tissue engineering. To 
further enhance mechanical strength, we have developed a novel layering technique that 
structurally reinforces collagen matrices, resulting in a non-linear increase in strength and 
stiffness of matrices.  
 
While collagen has excellent cell adhesive properties, for applications that involve 
contact with blood, collagen is known to be highly thrombogenic. As such, we have 
developed a sandwich molding technique to infuse recombinantly expressed elastin into 
collagen matrices. Triblock co-polymer elastin analogs, generated and characterized by 
our group and others, have shown the ability to undergo an inverse temperature phase 
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transition in aqueous solutions. Of specific mention is Lys-B10, the elastin analogue used 
in this study. The hydrophobic (Ile-Pro-Ala-Val-Gly) block, flank a central hydrophilic 
midblock (Val-Pro-Gly-Glu-Gly) that aids in co-ordination of water molecules in 
aqueous solutions. However, above the lower critical solution temperature, the 
hydrophobic endblocks co-accervate, yielding a hydrogel. We have shown the ability to 
not only modulate the mechanical behavior of recombinant elastin, but also introduce 
crosslinkable moieties into the elastin structure to promote intra/inter molecular 
crosslinking as well as crosslinking to other protein based materials or compatible 
substrates through the aid of labile lysine residues [238; 239]. Further, given the inverse 
transition temperature, we have been able to utilize elastin as a “glue” to adhere layers of 
collagen-elastin composites together. This further results in multi-ply composites, formed 
from single layer or multi-layer collagen lamellae infused with elastin. Consequently we 
created a series of thick composites that can be used for soft tissue repair and replacement 
and has potential utility in blood contacting applications. 
 
Tunable ECM mimetics with enhanced mechanical properties. Depending on the 
application, tissue replacements require the ability to modulate material mechanical 
properties. The present study noted the effect of a variety of processing techniques (initial 
gel concentration, layering of collagen lamellae and initial collagen gel thickness) on 4 
important mechanical properties – ultimate tensile strength, strain at failure, Young’s 
Modulus (stiffness) and thickness of matrices. As expected, increasing collagen 
concentration resulted in increased strength and stiffness for gels cast at the same 
thickness (4 mm). This is a direct result of greater amounts of protein present in mats. 
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Further, lower concentration lamellae potentially have micro-inhomogenieties or flaws 
which are masked when absolute protein amount increases, which, however, did not have 
an effect on strain to failure. Increasing the number of layers of collagen resulted in an 
increase in the strength (UTS) of collagen matrices. This is a surprising discovery as UTS 
is the force normalized to the cross-sectional area. As such, the strength and stiffness is 
expected to remain constant. However, interestingly, there appears to be structural 
reinforcement of collagen matrices when they are layered. We hypothesize that there is 
integration of the layers with each other, which potentially results in buttressing of 
fibrillar microstructure. We observed that during mechanical testing, that failure of 
matrices occurred through transverse fracture in the direction perpendicular to axial 
stretch, without delamination of collagen layers. Additionally, layered structures were 
thinner than multiple single layers, further suggesting collagen fibrils between layers 
were integrating between mats, and potentially generating a compressed randomly 
interwoven structure. While there was an increase in strength, stiffness and strain to 
failure with layering of collagen mats, increased layering did not result in significant 
increases in the aforementioned mechanical properties. The final variable altered to 
modulate mechanical properties of collagen lamellae was initial gel thickness. Initial 
collagen gel thickness variation resulted in an increasing amount of strength of matrices. 
Again, although normalized by thickness, the expected strength and stiffness should 
remain the same. However, we observed that higher initial gel thicknesses resulted in 
stronger gels, that dried to stronger mats. We further showed that thicker gels have 
greater packing and compaction, exhibiting a non-linear increase in thickness with 
increased initial collagen gel thickness.  Gels that are thicker, still, could potentially result 
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in stronger matrices.  8mm and thicker gels were not as stable and tended to shear parallel 
to the plane of casting when removed from the mold. We have developed a novel 
collagen based material with megapascal level strengths and stiffnesses in the 10’s to 
100’s of megapascals.  Thus, we have shown the ability to modulate mechanical strength 
as a function of initial gel concentration, layer of collagen mats, and initial collagen gel 
thickness; showing nonlinear improvement in strength, stiffness and strain at failure. 
 
Optimization of a novel protein-based laser ablation strategy and preservation of 
native protein structure. Ultraviolet lasers have been used in a variety of applications in 
medicine: psoriasis treatment [247], ophthalmologic applications [248], arthroscopy 
[249], laser-assisted vascular plaque ablation [250], and development of tissue 
engineering scaffolds [251; 252; 253; 254; 255]. Perhaps one of the most renowned 
examples of excimer laser ablation is in laser-assisted in situ keratomileusis (LASIK) eye 
surgery. The primary advantage of excimer laser use is that ablation of tissue/ materials 
takes place with minimal damage to the surroundings. Unlike thermal ablation, which is 
the basis for CO2 laser ablation, the benefit of excimer laser ablation is that it excites the 
molecular bonds sufficiently to dissociate them, ablate them, without thermal 
decomposition to elemental compounds. Further, the dissociated molecular products are 
cleared by an airstream which leaves a “clean” and non-denatured substrata that 
maintains native phenotype. Although non-thermal in nature, excimer laser ablation and 
other UV based optical ablation schemes generate small amounts of localized heat when 
maintained on a particular locus. Specific to tissue engineering, Nakayama and Matsuda 
used an excimer laser to improve compliance of polyurethane tubes by microablation of 
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holes of a variety of sizes improving compliance [255]. Engelmayr and colleagues used a 
similar approach to ablate adjacent (non-tangential, overlapping) holes in a polyglycerol 
sebacate scaffold. The resulting scaffold had a accordion-like honeycomb architecture 
with enhanced compliance and appreciable cellular alignment [253]. Further, Chollet et al 
report the use of excimer laser ablation to modulate cellular alignment. Specifically they 
report that 25 µm to 100 µm width RGD patterned substrates (separated by laser ablation) 
result in cellular alignment [252]. Of note is the fact that thermal energy build up is 
inevitable when a substrate is irradiated. As such, for our studies it was first crucial to 
determine the optimal conditions that result in collagen ablation without denaturation. 
Parameters such as fluence (spatial laser energy density) and rastering of the substrate, 
with multiple passes over the same region ensured collagen matrices were ablated with 
minimal thermal denaturation as demonstrated by ultrastructural analysis and differential 
scanning calirometry. Conventional laser ablation can be achieved in two primary modes 
– direct-write or rastering (over a mask). The former is typically more time intensive and 
involves “writing” a pattern of individual features on the substrate. The latter, however, 
involves moving a relatively larger laser spot across the substrate. When coupled with a 
mask that is laser opaque, features, as determined by the mask, are ablated. Although the 
theoretical resolution of excimer laser ablation is the wavelength of the beam (in our 
studies, 248nm), the practical resolution is typically 1 order of magnitude higher – 2-10 
µm. We have thus generated metal and aluminum-on-quartz masks that attenuate UV 
light, but allow transmission in 10 µm or greater gaps (features). Consequently, we have 
been able to rapidly fabricate detailed patterns on protein based matrices with high 
fidelity as demonstrated in Figure 3.3. To establish the efficacy of excimer laser ablation 
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of collagen matrices, collagen gels at 2.5 mg/mL initial concentration, 4 mm initial 
thickness and layered 4 times, were constructed, and excimer ablated. Thermal 
denaturation was determined by analyzing thermal transitions of collagen, which showed 
no measurable denaturation, and analyzing collagen ultrastructure – noting the retention 
of bulk and ablation edge native D-periodicity, 67nm banding patterns, and fibrillar 
structure. These results are similar to those reported in clinical practice with excimer laser 
ablation strategies yielding small (0.1 - 0.3 µm) regions of damage [256]. 
 
Generation of mechanically compliant protein substrates through laser ablation. 
Tissue engineered substrates need to mechanically match native tissue. For adequate 
tissue integration, it is critical that tissue mimetic substrates and scaffolds exhibit 
matching deformation characteristics to native tissue, to ensure there aren’t undue 
stresses on suture sites and to ensure the host tissue integrates favorably with grafts. One 
of the prime examples of this is compliance mismatch in synthetic vascular grafts and 
tissue engineered blood vessels. Several groups have reported the potential for early graft 
failure to occur at anastamotic sites due to mechanical mismatch [43; 257; 258]. We have 
shown the ability to generate a series of mechanically tunable collagen based constructs 
that have strengths and stiffnesses that exceed several soft tissues. To modulate the 
stiffness and compliance of these mechanically resilient and tissue mimetic substrates, we 
have designed and optimized a laser ablation scheme that does not adversely effect the 
native structure of collagen matrices – with retention of thermal properties and native 
ultrastructure. These ablated substrates were embedded in recombinantly expressed 
elastin and mechanically tested. The chosen ablation scheme, a triangular waveform 
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pattern with vertical strips resulted in highly compliant structures, wherein structures with 
approximating unity aspect ratios showed collagen strips extending and straightening 
prior to failure. We hypothesize that increased vertical strip thickness helps buttress 
collagen strips, keeping them anchored to the composite structure, aiding in in-plane 
extension. Conversely, thinner vertical strips could allow for twisting and out-of-plane 
bending of collagen waves which would consequently have a lower strain at failure, 
Design 2. As a consequence of large amounts of material removal, there was a decrease 
in ultimate tensile strength. However, tissue engineered microablated composites 
exhibited mechanical properties that mimic several tissues. The mechanical properties of 
unablated and microablated composites can be tuned comparing favorably to native 
tissue, ex. cartilage [259], ligament [259; 260], coronary artery [260], and carotid artery 
(1.76-2.64 MPa UTS),[261] Table 3.3.  We have developed a novel method to ablate 
micro-features for the further modulation of collagen as well as collagen elastin 
substrates to mimic the mechanical response of native tissue. We next determined the 
ability for collagen based matrices to be cellularized, and the potential for alignment on 
ablated matrices. 
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Unablated matrices 13.3 ± 2.19 18.0 ± 3.73 93.7 ± 19.8 
Ablated matrices 0.683 - 5.82 9.43 - 69.6 2.91 - 88.1 
Arteries#,$ 1.4-11.1 N.A 1.54 ± 0.33 
Veins$ N.A N.A 3.11 ± 0.65 
Cartilage∂ 3.7 - 10.5 N.A 0.7 - 15.3 






Cell supportive matrices with conforming cell adhesion. Several studies have noted 
the importance of cells in recapitulation of native tissue structure and function. For 
example, SMC in the vascular media act to both maintain contractility during pulsatile 
blood flow, as well as vasoconstrict as a function of neuronal or chemokine action. 
Further, cells in the myocardium and several other muscle tissue align in the direction of 
physiologic stress to aid in bio-mechanical function and contractility. For tissue-
engineered constructs, development of a cellular niche that complements cell adhesion, 
alignment and proliferation is quintessential to promotion of engrafted material healing 
and integration. The ability to align cells in vitro however has been attempted using a 
myriad of techniques. Notably, Zorlatuna et al have demonstrated that various 
nanopatterns on collagen membranes enhance vascular smooth muscle alignment as a 
function of channel dimension and length of cell interaction, needing up to 21 days for 
alignment [113]. A potential disadvantage of this technique is that micron level 
inhomogenieties in substrates, that result from large scale fabrication of constructs, may 
cause cells not to “see” the nanoscale features presented on surfaces. Engelmayr et al 
have demonstrated that cells seeded in micron sized pores created in polyglycerol 
sebacate result in localized cardiomyocyte alignment [253]. In contrast to their approach 
which uses geometric confinement to conform cells to specific material patterns, we 
propose a excimer–laser assisted ablation scheme that can potentially create ordered 
micro-ribbons that are intrinsically cell adhesive. Through the use of microfabrication 
technology and excimer laser ablation, we have developed cell adhesive substrates with 
precise micron-level patterns that ultimately demonstrate a facile method for the adhesion 
and conforming of cells as confluent cell layers on collagen matrices and are produced in 
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a matter of hours. Further, actin staining reveals that cellular cytoskeletal filament is 
indicative of the potential for cells to conform to the waveform pattern with potential 
anisotropic distribution. Further, cells appear to conform to the waveform pattern, 
allowing for rapid generation of large-scale cellularized tissue engineered substrates with 
structural, mechanical and rapid cellular adhesivity. Further studies could potentially 
enhance cellular adhesion and enhance preferential alignment of cells in the direction of 
collagen waves – providing a means to further tailor cellular anisotropy.  We have 
generated a highly scalable and strong collagen that is cell adhesive, results in cellular 
conformation to scaffolds and provides significant mechanical strength similar to native 
tissue.  Further, there is no additional need for cell binding additives, such as fibronectin/ 
vitronectin/ RGD, nano-/micro-patterning or buttressing of mechanical structure with 






Engineering of substrates for tissue repair and replacement have made several leaps over 
the past 20 years. Although a relatively old technology, the use of collagen-based 
technologies for tissue engineering is still a highly active area of research. The benefits of 
collagen are numerous, including its high species homology, ease of availability, intrinsic 
cell adhesiveness, strength, FDA approval, and ability for large scale fabrication and 
processing into constructs that are relevant for tissue engineering (as we have shown). 
This is the first report of a systematic study of the modulation of initial collagen gel 
concentration, gel thickness and layering of collagen lamellae to yield entirely collagen 
based materials suitable for tissue engineering. Further, we have shown an unexpected 
non-linear increase in strength and stiffness of matrices, due to buttressing and 
integration of multi-layer collagen constructs. Additionally, this is the first report of the 
use of excimer laser technology use for the ablation of biologically derived protein based 
matrices suitable for tissue engineering. Through the use of excimer laser technology, we 
have determined optimal parameters for the ablation of collagen matrices with high 
fidelity and preservation of native structure- determined using differential scanning 
calirometery and transmission electron microscopy. Further, with the addition of 
recombinantly expressed elastin mimetic peptides, nanofibrous composite extracellular 
mimetics have been created. Mechanical testing of ablated matrices show the ability to 
further modulate mechanical properties and improve compliance, stiffness and strength to 
better mimic a host of soft tissue. The critical dimensions we have chosen for ablation 
patterns, based on our and other’s work, result in the coordinated adhesion of rMSCs. 
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 CHAPTER 4 
Design of Tissue-Mimetic Arterial Grafts 
4.1 Introduction 
 
The design of a tissue engineered vascular graft to supplant diseased arteries requires 
consideration of mechanical, biological and clinical factors that influence behavior in 
vitro and in vivo [31; 262; 263]. To date, tissue engineered products have yet to replace 
the current “gold standard” of an autologous artery or vein. Much progress has been 
made in determining the key factors that contribute to the eventual success of a vessel 
graft. Mechanical requirements include (i) sufficient burst pressure to prevent 
catastrophic failure of the vessel and long-term fatigue resistance, (ii) compliance that 
approximates that of native vessels to prevent mechanical mismatch, and (iii) suitable 
suture retention strength to permit implantation and tolerate hydrodynamic and 
mechanical forces at the anastomoses. Biological and clinical considerations include (i) 
generation of a non-fouling luminal surface to prevent thrombosis, (ii) mediation of the 
immune response due to surgical trauma and potential graft rejection and regeneration, 
and (iii) evaluation in vivo [3; 262]. 
 Several groups have demonstrated the efficacies of various strategies that range 
from modifications of existing ePTFE/Dacron™ grafts to acellular / cellularized 
constructs to de novo engineering of tissue substitutes that mimic native vessels [264]. 
Tissue engineered blood vessels (TEBV) derived from cell-sheet tissue engineering and 
degradable synthetic polymer scaffolding has demonstrated early clinical success. 
Continued progress with several additional systems, suggest that these technologies will 
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continue to evolve [31; 45; 265]. Clinical success will be determined utilizing a “bottom-
up” approach where recapitulation of the fundamental features of the vascular wall, 
incorporation of key elements that obviate thrombosis and acute graft failure, and 
potentially the addition of a cellular component to ameliorate the unavoidable 
inflammatory response towards healing [86; 266; 267]. The strategy we have developed 
does not rely on the time consuming process of seeded cells to produce ECM, or 
approaches that utilize biodegradable scaffolds and lengthy bioreactor conditioning [9; 
73; 268]. It is postulated that this scheme will lead to shortened fabrication time, 
enhanced tissue integrity, and improved biological responses after in vivo implantation. 
Our lab and others have recently synthesized and characterized a series of elastin-
like protein polymers that consist of sequentially repeated amino acid blocks [269; 270; 
271; 272]. With the ability to easily modify these protein polymers: modify peptide chain 
length, consensus repeat sequence, and introduction of additional oligopeptide units, 
protein polymers can be produced with enhanced biological, thermodynamic, and 
mechanical properties. We have designed a series of elastin-like polypeptides that can be 
fabricated as films or other geometrical constructs, have robust mechanical properties, a 
high degree of resilience, minimal thrombogenicity, and long-term stability in vivo [273; 
274; 275; 276; 277; 278; 279; 280; 281]. 
Collagen, a vital component of the ECM milieu, is required for mechanical and 
biological support. Electrospinning, casting gels, and wet spinning have been the 
mainstay for large-scale production of collagen matrices for tissue engineering.  Although 
much progress has been made in the field of electrospinning, the use of organic solvents 
leads to collagen denaturation [282].  Likewise, the lack of mechanical integrity of 
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collagen hydrogels precludes their use as a structural component.  We have described a 
novel strategy incorporating collagen gels, dried to collagen lamellae to improve 
mechanical strength. Further, in developing collagen lamellae it was hypothesized that 
the inclusion of elastomeric protein components in collagen gels, forming 
interpenetrating networks, would yield modifiable mechanical and tissue-mimetic 
analogs for bioengineered vascular tissue fabrication. Consequently, composite structures 
were fabricated from recombinant elastin mimetics and collagen analogs with defined 
composition and microarchitecture, including collagen fiber orientation and packing 
density, without deleterious effects on the preservation of native collagen structure. 
The incorporation of bone marrow mesenchymal stem cells (BM-MSCs) within 
tissue engineered and biodegradable scaffolds has been widely reported.  Specific to 
vascular grafts, bone marrow derived mesenchymal stem cells have been shown to 
differentiate into endothelial progenitor like-cells [91; 92; 93; 94; 283] and other vascular 
wall cellular constituents, including fibroblasts [284] and smooth muscle cells [284; 285]. 
MSCs have also been shown to attenuate the inflammatory and immune responses 
associated with surgical trauma and implants. MSCs have the ability to direct 
macrophage polarization toward an M2 phenotype (healing/ resolution) over an M1 
phenotype (inflammatory), decrease antigen presentation, and promote secretion of anti-
inflammatory cytokines [97; 98; 101; 286; 287]. 
The work described details a novel approach that utilizes the aforementioned 
biopolymers in a combinatorial approach that yields protein based interpenetrating 
matrices with megapascal strengths and stiffness approximating native tissue. Mechanical 
characterization of non-crosslinked and crosslinked matrices show the potential to 
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modulate and tailor the mechanical strengths of these novel biologically derived 
polymers for a variety of vascular and other soft tissue engineering applications. Further, 
these novel materials show the potential for cellularization without the addition of 
dopants, and for blood contacting applications given their hemocompatibility and in vivo 
stability. This is the first report of the ultra-rapid fabrication of cellularized vascular 
grafts (synthesis within 4-24 h) compared to alternative techniques, which can take on the 
order of weeks to months. 
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4.2 Materials and Methods 
 
Isolation and purification of monomeric Type I collagen. Monomeric Type I rat tail 
tendon collagen was obtained by acid extraction from Sprague-Dawley rats (Pel-Freez 
Biologicals, Rogers, AR) following a procedure adapted from Silver and Trelstad [202].  
Briefly, rat tail tendons were extracted with the aid of autoclaved pliers and dissolved in 
10 mM HCl for 4  h at 25°C to dissolve the proteinaceous components.  Insoluble tissue 
and other contaminants were removed by centrifugation at 30,000g at 4˚C for 30 min 
with subsequent vacuum filtration through 20 µm, 0.45 µm and 0.2 µm filters.  The 
sterile filtered collagen in HCl was precipitated from solution by adding NaCl to a final 
concentration of 0.7 M.  The precipitated collagen was pelleted by centrifugation, 
redissolved in 10 mM HCl and dialyzed first against 20 mM phosphate buffer at room 
temperature, then at 4°C, second against 10 mM HCl at 4°C and finally against deionized 
water at 4°C.  The collagen was then frozen and lyophilized until use. 
 
Synthesis of a recombinant elastin-like protein polymer (ELP). Development and 
production of the ELP, LysB10, has been described elsewhere [239]. Briefly, a triblock 
amphiphilic copolymer was designed to contain hydrophobic endblocks and hydrophilic 
midblock.  The 75kDa polypeptide comprised 33 repeats of the pentapeptide sequence 
[IPAVG]5, and the 58 kDa midblock comprised 28 repeats of the sequence 
[(VPGAG)2VPGEG(VPGAG)2].  Flanking both the hydrophobic plastic endblocks and 
the hydrophilic elastic midblock were the crosslinkable amino acid sequences: [KAAK] 
which allow for amine-based crosslinking. Subsequent to expression in E. coli, protein 
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was extracted and purified using hot/cold centrifugation cycles and nucleic acid removal. 
Protein solutions were then dialyzed against water and lyophilized. 
 
Production of dense collagen-elastin interpenetrating networks (CEMs). Monomeric 
rat tail tendon collagen and Lys-B10 were dissolved in 10 mM HCl, at concentrations 
ranging between 0.6125 mg/ml - 5.0 mg/ml and various collagen and elastin ratios. 
Mixtures were neutralized using a gelation buffer (4.14 mg/ml monobasic sodium 
phosphate, 12.1 mg/ml dibasic sodium phosphate, 6.86 mg/ml TES (N-tris 
(hydroxymethyl) methyl-2-aminoethane sulfonic acid sodium salt, 7.89  mg/ml sodium 
chloride, pH 8.0) at 4˚C and were poured immediately into rectangular molds (10 x 8 x 
0.4  cm) for 24 h. Gels were subsequently placed in a fiber incubation buffer (7.89  
mg/ml sodium chloride, 4.26  mg/ml dibasic sodium phosphate,10 mM Tris, pH 7.4) at 
37°C for 48 h to promote collagen fibrillogenesis. Gels were then dried at room 
temperature under a steady air stream. Stacked CEM lamellae consisting of 2 to 4 layers 
were generated by serially drying additional gels on top of dried mats.  Some specimens 
were crosslinked in genipin in 1X PBS at 37°C for 24 h. 
 
Imaging of composite architecture. Optical microscopy, fluorescence microscopy, 
scanning electron microscopy (SEM), and transmission electron microscopy (TEM) were 
used to analyze the collagen structure pre and post embedment in elastin. For SEM 
studies, briefly, dry collagen lamellae were hydrated in water for 24 h and dehydrated in 
serial exchanges of ethanol-water mixtures from 30%-100%.  The samples were then 
critical point dried (Auto Samdri 815 Series A, Tousimis, Rockville, MD), sputter coated 
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with 8 nm of gold (208HR Cressington, Watford, England) and imaged at an accelerating 
voltage of 10 keV using a field emission scanning electron microscope (Zeiss Supra 55 
FE-SEM, Peabody, MA). To determine the ultrastructure and presence of D-periodicity 
in the fibrils, showing maintenance of native collagen structure, hydrated samples were 
prepared for TEM.  Samples in PBS were washed in 0.1 M cacodylate buffer and fixed in 
glutaraldehyde.  After washing in water, samples were partially dehydrated in ethanol and 
stained with uranyl acetate.  Samples were then fully dehydrated in ethanol, embedded in 
resin and polymerized.  Ultrathin (60 - 80 nm) samples were cut using a RMC MT-7000 
ultramicrotome (Boeckeler, Tucson, AZ).  Post-staining with uranyl acetate and lead 
citrate was followed by imaging using a JOEL JEM-1400 TEM (JOEL, Tokyo, Japan) at 
90 kV.  
 
Cellularization of CEM/ composite sheets with rat bone marrow derived 
mesenchymal stem cells (rMSCs). CEM lamellae were sterilized in 70% ethanol for 30 
mins. Scaffolds were dried and washed multiple times in PBS and incubated in media 
prior to seeding with cells. rMSCs were cultured in T75 flasks (Corning LifeSciences, 
Corning, NY) for 3 - 5 days until near confluence. Cells were used between the 3rd and 5th 
passage. Cells were trypsinized and resuspended at concentrations of 50,000, 100,000, 
and 200,000 cells/cm2 in full media. Cells were seeded on collagen constructs for 4 h, 12 
h and 24 h. Live/Dead™ staining (Invitrogen, Carlsbad, CA) and subsequent confocal 
microscopy (Leica SP5XMP) was performed on constructs, to determine optimal seeding 
time for confluence of cells on scaffolds. A subset of small diameter grafts (0.9 mm ID) 
were seeded with MSCs and murine dermal microvascular endothelial cells by infusion in 
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the lumen or seeding of adventitia with cells. For cell coverage quantification, 10x 
magnification images at 2048 x 2048 pixel2 resolution were obtained. A MATLAB script 
was written that decomposed red, green and blue layers from the images. Green images 
(live cells) were then thresholded based on script input and spatial coverage of cells per 
field determined. 
 
Fabrication of acellular and cellularized collagen-elastin nanofibrous grafts. Lys-
B10, dissolved in molecular grade water at 4˚C at a concentration of 100 mg/mL, was 
used to embed acellular or cellularized CEM matrices in a sandwich molding setup, 
Figure 4.1.  The setup was warmed to 25˚C to allow the liquid elastin mimetic to gel.  
The CEM-elastin composites were then removed from the glass support and trimmed to 
appropriate dimensions for testing.  Long sheets were rolled on 0.9 mm, 1.3 mm and 4 
mm ID glass mandrels, kept at 4˚C for 5 min to allow the elastin to go into a liquid state, 
and warmed to 25˚C to gel the elastin into one contiguous layer. 
 
Mechanical testing of planar composites. To simulate application in planar soft tissues, 
collagen sheets were cut into 20 mm x 5 mm strips and mounted onto a Dynamic 
Mechanical Thermal Analyzer V (DMTA V, Rheometric Scientific, Piscataway, NJ) with 
a gauge length of 10 mm, immersed in PBS at 37˚C. Samples were preconditioned 15 
times to 66% of the average maximum failure strain of initial test samples, and then 
tested to failure at 5 mm/min.  A total of 8 samples were tested for each group.  
Thickness of hydrated samples was measured using optical microscopy and then 
correlated to mechanical data to determine the ultimate tensile strength and strain at 
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failure.  Young’s modulus was determined by from the slope of the last 4% of the stress-
strain curve, in addition to ultimate tensile strength (UTS), stain at failure and Young’s 
modulus. 
 
Mechanical testing of tubular constructs. Pressure diameter testing to determine 
compliance and burst pressure of constructs was performed similar to previous reports 
[183].  Briefly, tubular collagen-elastin composites were mounted vertically, via luer-lock 
connectors with a 5 g axial weight, in PBS at 37˚C.  Grafts were inflated at a rate of 10 
mmHg/s, monitored using a pressure transducer (WIKA), and videographed for 
distention, using a CCD camera.  An edge detection program was written in MATLAB to 
identify and quantify radial distension of grafts based on the outer diameter and 
correlated to pressure readings. Compliance was determined as the percent difference in 
outer diameter at systole and diastole, divided by the pressure difference and initial 
diameter. Grafts were assumed to be incompressible for the range of compliance 
measurements. The pressure at which the graft started to leak, burst pressure, was also 
determined, n = 4 for 4 mm grafts and n = 4 for 1.25 mm grafts.  Suture retention strength 
of grafts was determined by cutting 4 mm x 4 mm square sections from planar sheets or 
longitudinal sections of the graft wall.  A 4-0 FS-2 prolene suture (Ethicon) was thrown 
through the middle of the square segment and pulled in the longitudinal direction using a 
DMTA (Rheometric Scientific), n = 4 for each of 4 grafts. Wall thickness measurements 
were made on 3 representative cross-sections of each graft. Each graft section was 
photographed. Image analysis using Adobe Photoshop allowed for the measurement of 
inner diameter, outer diameter and wall thickness, n=3 for each of 4 grafts. 
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Implantation of grafts in rat aortic interposition model. All animal experiments were 
approved by the Institutional Animal Care and Use Committee (IACUC) at Beth Israel 
Deaconess Medical Center. Female Sprague-Dawley rats ~275-300g (Charles River 
Labs, Wilmington, MA) were anesthetized using isofluorane (2% for induction and 1% 
for maintenance), shaved, sterilely prepped, and placed on a heating lamella at 37˚C. A 
vertical midline abdominal incision was made to expose the infrarenal aorta.  Rats 
received 100 U/kg of heparin prior to aorta clamping through the IVC.  The proximal and 
distal aorta were clamped using microclamps and a segment measuring approximately 1 
cm was resected and replaced with an acellular graft using eight to ten interrupted sutures 
(10-0 Prolene).  The abdominal incision was closed with 3-0 Prolene for the fascia and 
muscular layers, and 4-0 Prolene subcuticular suture for the skin. Rat received 
clopidogrel 75mg/kg per day for the first 3 days post-op. Samples (n=8) were explanted 
at 7 days.  
 
Histological analysis to evaluate graft performance. At experimental endpoints, 7 
days, rats were anesthetized (2.5% isofluorane induction, 1.5% isofluorane maintenance) 
and the thoracic cavity was exposed. Whole body fixation was performed. Briefly, an 18 
gauge needle was introduced into the left ventricle, and the animal was exsanguinated 
using 200mL of saline, and fixed using 200mL of 10% buffered formalin. Samples were 
processed for histology. Histology samples were paraffin embedded and sectioned at 5 




Computed tomography angiography (CTA) to evaluate graft performance. CTA was 
performed for 3-dimensional reconstruction and evaluation of patency of the implanted 
grafts. For each terminal timepoint (1week) 4 rats were anesthetized (2.5% isofluorane 
induction, 1.5% isofluorane maintenance) sterilely prepped and a sternotomy performed 
to expose the thoracic cavity. To facilitate acquisition of images, whole body 
exsanguination and fixation were performed and a radiopaque agent (Omnipaque, GE 
Healthcare, Milwaukee, WI) administered.  Vessels were then visualized using a 
NanoSPECT (Bioscan, Washington DC) and processed using InVivoScope (Bioscan, 
Washington DC). 
 
Statistical Analysis. Means and S.D. were obtained for all measurements, image 
analyses and mechanical data. Comparisons will be made using the Student’s t test for 
paired data, ANOVA for multiple comparisons, with Tukey post hoc analysis for 
parametric data.  Nonparametric tests will be carried out using the Kruskal-Wallis 







Rapid generation of acellular and cellularized vascular grafts. Acellular and 
cellularized vascular grafts, comprised of biologically derived collagen and biomimetic 
recombinantly expressed elastin have been rapidly produced. The overall schematic for 
the design, cellularization, and construction of the vascular grafts is outlined in Figure 
4.1. A solution of collagen and recombinantly expressed elastin were gelled, seeded with 
cells as desired, embedded in recombinant elastin, and rolled into tubes.   Following this 
process, protein-based tissue substitutes could be reliably fabricated within 60 min 
(acellular) and within 24 h (cellularized). 
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Figure 4.1. Schematic of fabrication scheme for acellular and cellularized grafts. (A) 
Collagen-elastin CEM lamellae are dried from collagen-elastin gels into defined 
thicknesses. (B) Lamellae can be cellularized with rMSCs at 100,000 cells/cm2. (C) 
Acellular and cellularized lamellae are embedded in elastin at defined thicknesses 
dictated by plastic shims (purple). (D) Acellular and cellularized composite sheets are 





Figure 4.2: Mechanical properties of genipin crosslinked CEMs. Introducing elastin into collagen gels resulted in an improvement 
in strength and stiffness (A,B,G,H). Increasing collagen concentration while maintaining elastin concentration resulted in weaker 
matrices (C,D I,J). Increasing the number of layers of a 1.25 mg/ml collagen, 1.25 mg/ml elastin CEM shows an unexpected 




Generation of interpenetrating networks with tunable mechanics dependent on 
collagen/elastin mixing ratios and layering. Collagen-elastin composites exhibited 
strengths on the order of 106 - 107 pascals, comparing superiorly to traditional collagen 
hydrogels or elastin networks [288].  Higher initial elastin concentrations resulted in 
regional inhomogeneities during collagen gelation, and were, thus, not pursued.  Elastin 
addition to collagen matrices during gelation resulted in a significant increase in strength 
and stiffness, Figure 4.2 A and G. Further, we noted that an elastin concentration of 2.5 
mg/ml and collagen concentration of 1.25 mg/ml and 2.5 mg/ml showed significant 
increase in strain to failure, over lower collagen-elastin ratios and higher collagen 
concentrations, Figure 4.2 B and D. Increasing collagen concentration from 2.5 mg/ml to 
5 mg/ml while maintaining elastin concentration at 2.5 mg/ml in initial gels, resulted in a 
decrease in UTS and a significant decrease in strain at failure, Figure 4.2 C and D.  
 
Characterization of layered CEMs was performed on 1.25 mg/ml collagen and 1.25 
mg/ml elastin matrices. Layered CEMs showed a significant increase in mechanical 
strength and stiffness from single layer matrices. UTS for single layer matrices (7.03 ± 
1.86 MPa) rose significantly for 2 layer and 4 layer constructs (13.0 ± 3.49 MPa and 12.5 
± 2.49 MPa). Similarly Young’s modulus rose from 1 layer to 2 and 4 layer constructs 
(58.4 ± 10.9 MPa, 95.7 ± 23.4 and 92.4 ± 13.5 MPa, respectively). This buttressing effect 
was limited to strength, and did not significantly decrease strain at failure (10 - 17 %) and 
stiffness (40 - 100 MPa), Figure 4.2 C, D & I. Thicknesses of matrices had a near linear 
relationship with initial collagen concentration, showing initial thicknesses of 14.9 ± 1.68 
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µm for 1.25 mg/ml collagen only and 115 ± 7.45 µm for 4 layered 1.25 mg/ml collagen, 
2.5 mg/ml elastin matrices. We have thus created a series of tunable collagen-elastin 
CEM matrices with modulatable strengths (2.43 – 13.0 MPa), strains at failure (12.8 – 




Figure 4.3. Representative stress-strain plots showing mechanical characterization of uncrosslinked 2.5 mg/ml collagen, 2.5 
mg/ml elastin CEM. (A) Preconditioning curves of 2.5 mg/ml collagen - 2.5 mg/ml elastin CEM, : first cycle, : 15th cycle. (B) 
Characteristic mechanical response of CEM (—), LysB10 (---) and 2.5 mg/ml collagen only matrix (), showing increase in 




Development of composite biomaterials with soft tissue-matching properties. 
Strong micron-thin crosslinked collagen-elastin CEMs result in the generation of 
mechanically tunable constructs, enabling mechanical matching of constructs to a variety 
of native tissue. However, given the UTS and stiffness of native vasculature (1.4 - 11.1 
MPa and 1.54 ± 0.33 MPa, respectively) we developed a series of constructs that were 
better mechanically matched. Further, given the high extensibility of 2.5 mg/ml collagen- 
2.5 mg/ml elastin matrices (30.7 ± 5.54 %), this design was chosen for further study. 
Uncrosslinked CEMs of the aforementioned concentrations were constructed and 
mechanically tested. The addition of elastin during collagen gelation, increases matrix 
strength and stiffness, over collagen or elastin alone, and resulted in mechanical 
properties more closely matching native vascular tissue, Figure 4.3 B. UTS of 
uncrosslinked CEM matrices was 2.33 ± 0.406 MPa, strain to failure was 30.1 ± 5.61 % 
and stiffness was approximately 50% decreased compared to crosslinked matrices, 9.39 ± 
2.66 MPa, Figure 4.3 B. Resilience, a measure of recovered energy during unloading of 
matrices, shows much of the energy is recovered during subsequent loading-unloading 
cycles, comparing favorably to tissue, with minimal energy loss during cyclic loading. 
The resilience of CEM matrices was 72.9 ± 5.91 %, Figure 4.3 A. CEM matrices showed 
enhanced mechanical properties compared to constitutive materials alone. 2.5 mg/ml 
collagen only matrices had a UTS of 0.474 ± 0.0711 MPa, a strain to failure of 21.1 ± 
3.32 %, and a Young’s Modulus of 2.15 ± 0.690 MPa. Based on previous studies from 
our group, LysB10-only constructs showed an UTS of 2.88 ± 0.910 MPa, a strain to 
failure of 430 ± 34.0 % and a Young’s Modulus of 0.530 ± 0.0200 MPa. 
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Table 4.1: Mechanical characterization of uncrosslinked 2.5 mg/ml collagen, 2.5 

















mm# 285 ± 30.4 2.36 ± 0.194 1354 ± 293 38.0 ± 3.46 
Implant 
Graft 4.0 
mm# 602 ± 38.2 2.04 ± 0.330 1237 ± 143 72.5 ± 3.59 
Venous% 250* 0.7 - 2.6 1600 - 2500 180 - 250 
Arterial % 350-710* 4.7 - 17.0 2200 - 4225 88 - 200 
Synthetic 
grafts 200-600 0.2 - 1.9 2580 - 8270 250 - 1200 





Biomimetic vascular grafts with mechanical matching to native vasculature. Three 
critical mechanical features that need to be maintained for success of vascular grafts are 
compliance, burst pressure and suture retention strength. Compliance of 1.3 mm graft and 
4 mm grafts closely resembled that of native saphenous vein, 2.36 ± 0.194 %/100mmHg, 
2.04 ± 0.330 %/100mmHg, and 0.7 - 2.6 %/100mmHg, respectively. Burst pressures of 
tissue engineered grafts were significantly higher than physiologic/pathophysiologic 
range, 1354 ± 293 mmHg for 1.3 mm grafts and 1237 ± 143 mmHg for 4 mm grafts. 
Suture retention strength was a function of number of layers within the graft wall. The 
1.3 mm grafts had 4-5 layers of composite rolled, Figure 4.4, and 4.0 mm grafts had 8-9 
layers. The suture retention strength increased from 38.0 ± 3.46 gF to 72.5 ± 3.59 for 1.3 
mm grafts to 4 mm grafts. Further, we have shown the ability to modulate wall thickness 
as a function of layering/rolling of grafts. 1.3 mm grafts were constructed from a 20 mm 
composite sheet rolled on a 1.3 mm mandrel. Consequently grafts had a wall thickness of 
285 ± 30.4 µm. Similarly, 4 mm grafts were constructed from 100 mm composite sheets  
rolled on a 4 mm mandrel, and thus had a thicker 602 ± 38.2 µm wall. The observed 
mechanical strengths approximate or supersede native vasculature and synthetic grafts, 
Table 4.1.  
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Figure 4.4. Meso- and Ultrastructure of CEM grafts. (A) Photo of unimplanted graft 
segment, (B) long graft segment showing kink resistance,  (C) Van Geison stained cross-
section of graft wall clearly delineating layers: collagen in CEM stained red, elastin 
yellow, scale bar 100 µm, (D) SEM of graft cross-section, scale bar 500 µm, (E) SEM of 
graft wall showing contiguous elastin layer and site of rolling initiation, scale bar 100 
µm, (F) SEM of elastin structure on lumen of graft, scale bar 1 µm, (G) SEM of fibrous 
structure of 2.5 mg/ml collagen only lamella showing fibrillar collagen, 50 kX, scale bar 
1 µm, 10 kX inset showing global nanofibrous morphology, scale bar 2 µm, (H) SEM of 
fibrous structure of 2.5 mg/ml collagen, 2.5 mg/ml elastin CEM lamella showing fibrillar 
collagen “decorated” with elastin, 50 kX, scale bar 1 µm, 10kX inset showing global 
nanofibrous morphology, scale bar 2 µm, (I) SEM of nanofibrous region of graft 
impregnated with elastin, scale bar 1 µm. (J) TEM of CEM lamella showing 
characteristic collagen banding, scale bar 1 µm. (K) and (L) TEM of cross-section of 
elastin (top) embedded CEM showing preservation of native structure, scale bar 10 µm 
and 0.5 µm respectively. 
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Graft structure and composition. Preliminary studies involving elastin coated on 
ePTFE have demonstrated the hemocompatiblity of certain recombinant elastin 
formulations [289; 290; 291]. Consequently, it is of critical importance that vascular 
grafts have a non-thrombogenic lumen, while ensuring mechanical integrity [292]. We 
have generated vascular grafts with a variety of inner diameters using CEMs embedded 
in an elastin matrix. Dry weight of elastin impregnated sheets shows a significant 
increase in elastin spatial concentration in constructs, 1620 ± 100 µg/cm2, over CEMs 
alone, 1400 ± 89.8 µg/cm2. Compared to collagen matrices alone, which have a spatial 
concentration of 772 ± 62.0 µg/cm2, elastin impregnated CEMs, and resultant grafts are 
47% collagen and 53% elastin by dry weight. In vivo studies detailed herein utilize a 1.3 
mm ID graft, Figure 4.4 A and B. Van Geison staining of collagen, shows collagen (red) 
and elastin (yellow) localization in rolled graft, Figure 4.4 C. Since red staining is 
predominant in sections, elastin within CEM structures cannot be visualized optically. 
Van Geison stained sections show elastin (yellow) coats the lumen of grafts, Figure 4.4 
C. Ultrastructure of rolled grafts was noted by SEM of critical point dried graft sections. 
1.3 mm ID grafts had 4 - 5 rolled layers and 4 mm ID grafts had 8 - 9 rolled layers, 
Figure 4.4 D and E. The luminal surface has a uniform coating of elastin, including 
regions where rolling is initiated, Figure 4.4 E. Further, the uniform layer of elastin was 
confirmed by en face visualization of elastin on the luminal surface, which has a distinct 
fibrillar structure, Figure 4.4 F, compared to collagen or CEM matrices, Figures 4.4 G & 
H. We have, thus, demonstrated the ability to generate mechanically robust tubular 
collagen-elastin matrices with uniform luminal elastin which could potentially mediate 
acute thrombotic responses. 
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Preservation of fibrillar collagen micro- and ultra- structure. Native collagen 
microstructure and ultrastructure maintenance is essential to avoid premature 
degradation, immunogenic responses and loss of mechanical integrity. Collagen matrices 
alone show nanofibrous network formation with collagen fibrils measuring 83.1 ± 9.44 
nm, Figure 4.4 G. However, when co-gelled with elastin, resulting in CEMs, fibrillar 
matrices still formed, with collagen fibrils “decorated” with elastin, Figure 4.4 H. 
Collagen fibril diameter increased to 88.1 ± 11.2 nm, but was not significantly different 
from matrices gelled without the addition of elastin.  CEM matrices were then embedded 
in elastin, in a sandwich molding process that infused elastin into the fibrillar CEM 
network, filling the nano-porous matrix, Figure 4.4 I. Fibrillar collagen without native D-
periodicity is insufficient in recapitulation of native matrices. We have shown the ability 
for collagen mats, Figure 4.4 G, to develop fibrillar matrices with native D-periodic 
banding patterns (unpublished). However, we have also demonstrated, with the aid of 
uranyl acetate staining of CEMs, the preservation of D-periodicity within the collagen 
component, Figure 4.4 J. Additionally, after embedding with elastin, fibrillar matrices 
and D-periodicity is maintained, Figures 4.4 K and L. It is apparent through elastin 
staining that infusion of collagen lamellae has occurred with a thin uniform layer of 
elastin asymmetrically exposed, Figures 4.4 K and L. We have thus shown ability to 
generate nanofibrous collagen-elastin interpenetrating networks with enhanced 




Figure 4.5. Cellularization of CEM. (A-I) Planar CEM seeded with rMSCs at 50 000, 
100 000 and 200 000cells/cm2, showing cell adhesion (4 h – 12 h) and spreading (12 h - 
24 h).  
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Figure 4.6. Live/Dead staining for cell viability on graft surfaces. (A) Planar CEM 
seeded with rMSCs at 100 000 cells/cm2 for 24 h embedded in elastin. (B) Cellularized 
composite imaged after 3 days. A series of 0.9 mm grafts rolled either with infused 
superficial elastin facing the lumen or infused CEM facing the lumen (E-F) were 
constructed.  (C) rMSCs were seeded on adventitial side (CEM exposed) of rolled grafts 
at 100 000 cells/cm2 for 24 h. (D) No cells present on luminal elastin side. (E) rMSCs 
were seeded on luminal side (CEM exposed) of rolled grafts at 100 000 cells/cm2 for 24 
h, (F) murine dermal microvascular ECs were seeded on luminal side (CEM exposed) of 
rolled grafts at 100 000 cells/cm2 for 24 h. Scale bar is 300 µm. 
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Rapid cellularization of CEMs result in generation of cellularized vascular media 
equivalents. Sterilized CEM matrices were seeded with rMSCs at various concentrations. 
Live/DeadTM staining showed low cell adhesion at 4 h with absence of filapodia and cell 
spreading for all concentrations, Figure 4.5 A, D and G. Quantification of cellularization 
at 4 h showed 6.93 ± 2.23 %, 16.2 ± 2.57 %, 28.1 ± 3.50 % confluence for respective 
spatial seeding densities of 50 000, 100 000 and 200 000 cells/cm2. At 12 h, lower cell 
concentrations show moderate cell adhesion, but high cell concentrations show high cell 
attachment and spreading, Figure 4.5 B, E and H. Quantification of cellularization at 12 h 
showed 26.3 ± 3.64 %, 56.2 ± 4.20 %, 84.9 ± 6.28 % confluence for respective spatial 
seeding densities of 50 000, 100 000 and 200 000 cells/cm2. At 24 h post seeding, cells 
seeded at 50 000 cells/cm2 witnessed moderate adhesion with cell spreading, but cells 
seeded at 100 000 and 200 000 cells/cm2 showed near confluence, Figure 4.5 C, F and I. 
Quantification of cellularization at 24 h showed 59.6 ± 12.1 %, 85.6 ± 6.06 %, 87.8 ± 
6.35 % confluence for respective spatial seeding densities of 50 000, 100 000 and 200 
000 cells/cm2, respectively. We determined the minimal cell seeding concentration for 
confluence of CEMs with good cell adhesion and spreading within 24 h (100 000 
cells/cm2 over 200 000 cells/cm2, p=0.82). Consequently, CEMs seeded at 100 000 
cells/cm2 for 24 h were carried forth to elastin embedding. Cellularized constructs were 
embedded in elastin using a sandwich molding process, which resulted in a reduction of 
cells. Imaging of cells immediately after embedding and after 3 days showed cell 
viability within composites and proliferation, Figure 4.6 A and B, respectively. 
Quantification of cellularization immediately after elastin embedding showed 12.0 ± 3.39 
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% confluence, compared to 3 days post embedding, 25.2 ± 5.47 %. In a similar approach, 
we seeded MSCs and ECs luminally and abluminally (MSCs only) and showed 
preferential adhesion and near confluence in 24 h of seeding, Figures 4.6 C-F. We have 
thus shown the ability to rapidly cellularize and embed CEM matrices with elastin. 





Figure 4.7 Implantation of a 1cm long 1.3mm ID aortic interposition graft in the infrarenal suprailiac position. Gross 
morphology of the graft was noted: (A) Photo of graft at implant showing reddish color of blood flow, (B) Photo of graft at explant 
after exsanguination and perfusion fixation. (C) Evaluation of patency of lumen using contrast based angiographic computed 




Patent small diameter vascular grafts in vivo. 1.3 mm ID vascular grafts were 
implanted for 1 week in a rat aortic interposition model. Rats were dosed with 
clopidogrel for 3 days post-op. Grafts could be easily trimmed to desired dimensions for 
implant (1 cm long), Figure 4.7 A. Grafts appeared to be fully perfused upon release of 
clamps and allowed for visualization of blood flow, Figure 4.7 A. Upon explant, grafts 
appeared patent with minimal adventitial adhesion to abluminal wall, Figure 4.7 B. CTA 
of perfusion fixed interposed grafts show maintenance of graft patency and lack of 
aneurysmal dilation, Figure 4.7 C. Visual observation of graft luminal surface showed no 
thrombus or visible intimal hyperplasia. Graft integrity was maintained with identifiable 
staining of ECM based graft components, Figure 4.8 A. There appears to be the 
development of a cellularized neointima which stained positive for collagen, 
mononuclear cells, and entrapped red blood cells, Figure 4.8 A, B and C.  We have thus 
shown the ability for ECM mimetics to rapidly generate grafts that mimic the native 




Figure 4.8 Evaluation of graft morphology and cellular infiltrate. (A) Masson’s Trichrome staining of ECM of graft sections 
showing CEM layers in blue (Lys-B10 does not stain positively), and neointima, scale bar 100 µm, (B) magnified image showing 
trapped red blood cells and blue staining of neo-collagen matrix in neointima, (C) thin layer of mononuclear cells adherent on 





Bioinspired matrices with tunable mechanical properties and tissue-mimetic 
microarchitecture. Collagen and elastin matrices have been used for several decades 
either independently, in combination or as composites with other materials for tissue 
engineering [8; 112; 293]. Although of great relevance and importance to tissue 
engineering and design of materials for implantation, mechanical failure of collagen gels 
has hampered efforts to fully utilize the properties of collagen. Several techniques have 
been developed to: aid the localized deposition of collagen on non-biologically derived 
matrices, recapitulate the ECM environment using synthetic polymers, or process 
collagen.  The last of which often results in denatured variants that lack native structure. 
Moreover, the mechanical strength of traditional processing techniques for collagen 
matrices do not approximate native tissue. However, through the use of novel fabrication 
techniques, enhanced dehydration and compaction of collagen gels, and co-gelling with 
recombinantly expressed elastin, we have generated a series of mechanically tunable 
matrices that support cell adhesion and proliferation while exhibiting mechanical 
properties that are similar to vascular and other soft tissue. Mechanical strength and 
stiffness can be varied through the judicious selection of initial gel formulations, 
concentrations, gel thicknesses, layering of matrices and crosslinking. The addition of 
another matrix component during gelation (elastin-mimetic polypeptides), which 
decorates collagen fibrils, causes an increase in strain to failure and increased strength of 
matrices. Enhanced mechanical compliance due to the ability of elastin-mimetic 
polypetides to disrupt the inter-fibrillar structure of collagen, may result in decreased 
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collagen fibrillar branching and adhesions, allowing for enhanced fibril pullout and 
transition from brittle to ductile fracture.  This further allows enhanced fibrillar 
slippage/pullout and withstanding additional force prior to formation of defects leading to 
failure as seen in many particulate reinforced composites [294]. Matrices of this type 
have been found in bone, that act as sacrificial bond forming matrices that allow for a 
“hidden length” of fibrils to be found, which may further explain the enhanced strain to 
failure of composite matrices over collagen only matrices [295]. Additionally, elastin-
mimetic polypeptides may act as a “glue” to better adhere adjacent collagen fibrils, 
resulting in higher strengths [295]. Hydroxyl groups and sulphydryl groups in collagen 
and recombinant elastin matrices enable micro-crosslinks, both physical and chemical 
(Van der Waal’s, ester, thioester) to form between monomers during gel dehydration. 
This has been shown to enhance mechanical strength of matrices [239; 296; 297; 298]. 
Through the modulation of macroscale crosslinks, due to the addition of genipin, we note 
further strengthening of uncrosslinked matrices when crosslinked. We show the ability to 
create mechanically resilient structures that exhibit high failure strain and enhanced 
compliance when used to form rolled tubes.   
 
Mechanically matching biomimetic vascular grafts. For the long-term success of 
vascular grafts, 3 fundamental mechanical requirements exist: compliance matching 
native vascular tissue, burst pressures exceeding physiological/ pathophysiological 
ranges, and suturability. Compliance mismatch has been indicated in the failure of several 
small diameter vascular grafts [258; 299]. Further, it is seen that autologous tissue, when 
exposed to native flow regimes, remodels to acquire a phenotype and morphology similar 
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to native arteries [300; 301; 302]. Thus it is required that vascular grafts remodel while 
integrating into native tissue. To this end, several groups have investigated the use of 
porous biodegradable matrices that allow cellular infiltration (or are pre-seeded with 
cells) to allow and facilitate remodeling [230; 303; 304]. Given the long culture times, 
contamination risk, unclear cell source and cost, several of these strategies lack wide-
scale clinical applicability [31]. The current trend in the field has been to recapitulate the 
native vascular environment in vitro using cell based approaches to secrete ECM. These 
scaffolds are then decellularized and the matrix they form used for engineered tissue [9]. 
While this approach has shown some clinical applicability, similar issues of long culture 
times, contamination, cell source and cost limit widespread use and utility in acute 
indications. The matrix formed, however, has been shown to be mechanically similar to 
native tissue and possesses strengths suitable for implantation [9; 45; 262]. We propose a 
novel approach that obviates some of the aforementioned limitations, by rapidly 
generating ECM-based vascular grafts, not secreted by cells. Grafts composed of purified 
Type I collagen, for strength and structural support [139; 183], and recombinantly 
expressed elastin, for thromboresistance [183; 289; 290; 291], demonstrate similar 
mechanics to native tissue. Compliance of tissue engineered grafts approximate that of 
native human saphenous vein (typically used for bypass surgery) and have burst pressures 
an order of magnitude higher than that ever reached in human vasculature. Grafts have 
sufficient suturability allowing for ease of implantation, with high durability (resistance 
to delamination of rolled layers). 
 
Cellularized vascular grafts on demand. The design and fabrication of a cellularized 
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tissue mimetic composite within a clinically relevant timeframe for implantation has until 
now eluded the field of vascular tissue engineering. To date, the most successful 
cellularized construct implanted by L’Heureux et al in a variety of animal, non-human 
primate, and human models, take on the order of 3-6 months to generate [31]. While there 
is a market and scope for their technology, several limitations exist. Their method uses 
cells to secrete ECM, which is then rolled and allowed to adhere. In a similar approach, 
ECM matrices from cells seeded on biodegradable polymers presents a novel solution to 
potentially avoid delamination of rolled layers [45]. Dahl et al’s strategy has shown 
efficacy in large animal models, but the time to produce grafts, limit utility for emergent 
indications. The advantage of the approach we propose is the rapidity with which 
cellularized constructs can be created. Herein, we describe a novel strategy that allows 
for the generation of cellularized vascular grafts within 24 h, while other techniques 
require week-month time frames. While the total time for the fabrication of acellular 
grafts is less than 60 min, cellularized CEM matrices is granted for 24 h to ensure cell 
adhesion, proliferation and near confluence. Cells are allowed to proliferate on collagen 
matrices prior to embedding with elastin, rolling on a 1.3 mm or 4 mm mandrel and re-
gelling the elastin to form one contiguous layer. This novel technique allows for the rapid 
generation of cellularized vascular grafts that have sufficient mechanical strength and 
stability for implantation. MSCs provide a convenient source for the population of 
vascular grafts, given their ease of isolation from a variety of sources (bone marrow, 
peripheral blood, adipose tissue). Mesenchymal stem cells have been shown to 
differentiate into endothelial progenitor like-cells [91; 92; 93; 94; 283] and other vascular 
wall cellular constituents, including fibroblasts [284], and smooth muscle cells [284; 
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285]. This ability eliminates the need to isolate specific cell types for site specific 
repopulation engineered vascular constructs.  A wide literature that suggests the ability of 
MSCs to attenuate the inflammatory and immune responses associated with surgical 
trauma and implants. Work from Badylak’s group, and others, has shown the potential for 
the incorporation of bone marrow mesenchymal stem cells within tissue engineered and 
biodegradable scaffolds that modulate the inevitable host tissue inflammatory response. 
They have shown the ability for BM-MSCs to secrete a host of factors that ultimately 
direct the infiltrating macrophage response toward a M2 resolution (healing phenotype) 
over a M1 inflammatory phenotype. Further they have been shown to down-regulate 
MHC and costimulatory molecule expression, decrease inflammatory cytokine 
expression (TNF-α, IL-12, IFN-γ), increase anti-inflammatory cytokine expression (IL-
10), promote T-reg proliferation, and interfere with lymphocyte replication [97; 98; 101; 
286; 287]. Another interesting aspect of MSCs is their ability to modulate the 
thrombogenicity of blood contacting surfaces. Work done by Song Li’s group and Chris 
Breuer’s group has shown the anti-thrombogenic potential for MSCs on vascular grafts 
[86; 266; 267; 305]. While we have yet to test the efficacy of MSC immunomodulatory 
and anti-thrombogenic potential in vivo, we have constructed MSC based media 
equivalents, near confluent MSC or EC intima, and MSC seeded adventitia in a short, 
clinically relevant, one day time frame that can potentially revolutionize the current 
standard of care. 
 
Non-thrombogenic vascular grafts. The 3 critical requirements for vascular grafts when 
implanted are: (i) durability to withstand continuous pulsatile blood flow; (ii) maintain 
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patency; and (iii) resist aneurysm formation. To assess the ability of tissue engineered 
vascular grafts to avoid catastrophic failure, resulting from (i)-(iii) mentioned above, it is 
critical to test grafts in a variety of animal models prior to implantation in vivo. While in 
vitro characteristics of mechanical robustness and fatigue resistance are critical, tissue 
engineered grafts are dynamic systems that integrate and function in a synergistic manner 
with host tissue. To this end, we developed small diameter vascular grafts for surgical 
implantation in a rat aortic interposition model. The advantage our model is: (1) the high 
blood flow and “harsh” biomechanical forces that are imposed on interposed vessels, and 
(2) there that are no major collateral vessels to compensate peripheral tissue perfusion, 
allowing definitive evaluation of graft performance. We strived to further create a 
challenging model to test efficacy of vascular grafts by limiting post-surgical dosing of 
anti-platelet medications to just 3 days post op, with no concomitant anti-thrombotic 
agent administration. Tissue engineered vascular grafts showed good success, without 
note of occlusive thrombi or neointimal hyperplasia at one week. We noted integration 
and healing of the anastamoses. CTA showed patency of grafts with no appreciable 
aneurysmal dilation. Histological evaluation showed no evident calcification, coverage of 
EC-like cells on the luminal surface, neo-collagen matrix synthesis, with minimal 
leukocyte infiltration and no occlusive thrombus presence. While 1 week timepoints are 
clinically relevant to establish short term efficacy of graft utility, longer timepoints (1 
month, 3 month) will establish the full healing response and the ability for grafts to 




We report the production of a novel series of modulatable biomaterials that show tissue 
mimetic responses based on isolated and purified Type I collagen and recombinantly 
expressed elastin. Materials show the ability to be mechanically tailored to match a 
variety of tissue based substrates by the variation of initial collagen and elastin 
concentrations. We show an unexpected increase in mechanical strength (UTS) and 
stiffness (Young’s Modulus) as a function of network interpenetration and densification 
through matrix layering. To further modulate mechanics, genipin crosslinking was used. 
Through the use of CEMs embedded with recombinantly expressed elastin in a sandwich 
molding process, we demonstrated the ability to rapidly create rolled tubular constructs 
that exhibit mechanical properties similar to native tissue. We have demonstrated that the 
native ultrastructure of collagen is preserved with the addition of elastin in CEMs as well 
as the cellular adhesiveness. CEM matrices show rapid cellular adhesion, spreading and 
proliferation at modest cell densities (100 000 cells/cm2). Since only 5 x 106 cells are 
required for a 4 mm ID graft, the potential for their use with a variety of cell types in 
clinical applications is conceivable. Embedding cell seeded constructs with elastin and 
subsequent rolling allows for the formation of tubular cellularized composites. This is the 
first report of MSC based media equivalents, which have the potential of modulating the 
inflammatory environment healing vascular grafts generated in 24  h. Implanted vascular 
grafts show excellent stability and lack of neointimal hyperplasia, aneurysmal dilation or 
luminal thrombosis/ stenosis. Given the ability to modulate mechanics, cellularized grafts 
and stability of implanted grafts in vivo, we believe this presents a paradigm in the 
development of extracellular matrix based materials and vascular grafts. Future studies 
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will involve the validation of acellular and cellularized grafts in rat (for longer time 
points, four weeks and three months) and higher animal models, the use of autologus 
MSCs cells from animals for seeded grafts, and potentially other cells types, such as 
induced pluripotent stem cells. 
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CHAPTER 5 
Summary and Future directions: 
5.1 Summary 
 Chapter 1 details the need, requirements and future of vascular grafts. Vascular 
disease results in the decreased utility and availability of autologous vascular tissue for 
small diameter (<6 mm) vessel replacements. While synthetic polymer alternatives to 
date have failed to meet the performance of autoglogus conduits, tissue engineered 
replacement vessels represent an ideal solution to this clinical problem. Ongoing progress 
requires combined approaches from biomaterials science, cell biology, and translational 
medicine to develop feasible solutions with the requisite mechanical support, non-fouling 
surface for blood flow, and tissue regeneration. Specific to mechanical considerations, 
grafts must have (i) sufficient burst pressure to prevent catastrophic failure of the vessel 
and long-term fatigue resistance, (ii) suitable compliance that approximates that of the 
native vessel to prevent mechanical mismatch, and (iii) sufficient suture retention 
strength to permit implantation and tolerate hydrodynamic and mechanical forces at the 
anastomosis. Biological and clinical considerations include (i) generation of a non-
fouling luminal surface to prevent thrombosis, (ii) mediation of the immune response due 
to surgical trauma and potential graft rejection and regeneration, and (iii) demonstrated 
efficacy in vivo. 
To this end, we have utilized a bottom-up approach to individually target the mechanical 
aspects, as described exclusively in Chapter 2 with collagen alignment, and parts of 
Chapter 3 and Chapter 4. While several different materials have been developed and 
characterized during the course of this investigation, select prototypes have aided in 
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intelligent design of next level constructs. For example dehydration strategies from 
Chapter 2 were employed in Chapter 3. Further, lessons learnt from composite mechanics 
and fabrication schemes in Chapter 3 were translated to developing interpenetrating 
networks and vascular grafts in Chapter 4. Given the wide range of materials and material 
properties elucidated during the course of this work, we postulate that these materials can 
be used for a variety of tissue engineering applications. 
 
Collagen has been used widely as a biomaterial because of its strength, high species 
homology, known isolation and production protocols, and processability into higher order 
structures. However, prior processing techniques have resulted in a lack of ultrastructural 
control and mechanical strength as well as restricted construct size (nano/meso scales).  
This in turn prevented large-scale fabrication of tissue engineered constructs. More 
specifically, existing processes for making collagen constructs result in biomaterials that 
lack mechanical strength, integrity and structural support. The use of collagen based 
biomaterials has further been limited given its structural isotropy. The work described 
herein however outlines fabrication of micro-thin nanofibrous collagen matrices with (i) 
stretch induced anisotropy (Chapter 2), (ii) integration of layered structures to improve 
mechanical strength (Chapter 3), (iii) laser ablation schemes to create higher order 
structures mimicking native tissue structure, morphology and mechanics and alignment 
of cells on scaffold architecture (Chapter 3), (iv) development of composites for use as 
soft tissue replacements, and blood contacting surfaces (Chapter 3 and 4), and (v) 
potential for use in conjugating moieties that will allow for enhanced tissue repair, tissue 
regeneration, drug delivery and mechanical strengthening (future work). In all we have 
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created defined tissue mimetic architectures that guide cell and tissue morphology and 
hierarchical development of 3D tissue in vitro and in vivo.  
 
In Chapter 2, we present a method for the fabrication of micro-thin nanofibrous collagen 
matrices with stretch-induced anisotropy.  Monomeric rat tail tendon Type I collagen was 
neutralized in a phosphate buffer to yield large centimeter scale gels.  PAGE analysis, 
microdifferential scanning calorimetry and transmission electron microscopy confirmed 
reconstitution of collagen and characteristic 67nm D-periodic banding.  Collagen gels of 
varying concentration, 0.3125mg/mL-2.5mg/mL, were mounted on an automated stepper 
motor which stretched the gels to 0%, 10% and 20% strain, at rates of 3um/s and 
300um/s.  Fast Fourier Transforms (FFT’s) of scanning electron micrographs showed 
collagen nanofibrils (~80nm) preferentially aligning in the direction of stretching, with 
dependence on stretch amount and rate. Further, structural anisotropy translated to 
mechanical anisotropy, yielding significantly higher ultimate tensile strengths and 
Young’s moduli in the direction of alignment, compared to directions perpendicular to 
alignment or in unaligned matrices. In summary, we present the generation of a novel 
centimeter scale collagen based construct, with nanofibrous anisotropy; superior strength, 
alignment and construct size to previously published techniques; and potential utility in 
cardiovascular, dermal and other soft tissue engineering applications.  
In Chapter 3, we showed that through the use of mechanical reinforcement of collagen 
matrices, and excimer laser ablation, mechanically compliant 3D tissue mimetic supports 
can be generated that support cellular adhesion, proliferation and alignment of cells, 
ultimately acting as scaffolds for soft tissue engineering. Collagen has been widely used 
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for the development of materials for repair, augmentation or replacement of damaged or 
diseased tissue. However, current processing techniques have limited its ability to be 
processed into large tissue constructs. Further, dense collagen films lack the mechanical 
compliance that is required to adequately mimic tissue. Conventional processing 
techniques for synthetic materials have resulted in the development of anisotropic 
matrices that can be mechanically tuned to by using mechanical, thermal or laser ablation 
schemes. Herein we describe a facile method for the large-scale fabrication of 
biologically derived materials through mechanical reinforcement and excimer laser 
ablation to create 3D tissue mimetic constructs that are mechanically tunable and support 
cellular adhesion and alignment. Collagen gels cast in a phosphate buffer were dried to 
form dense collagen mats. Subsequent gels were dried atop lamellae to create multilayer 
constructs. This series of novel collagen based substrates interestingly possessed a range 
of megapascal level strengths (1 - 15 MPa) and stiffnesses (2 – 100 MPa) which are a 
function of collagen concentration, collagen matrix thickness, crosslinking and a novel 
layering technique that results in matrix densification. To show potential utility in blood 
contacting applications, we developed a novel strategy to embed collagen matrices with 
recombinantly expressed elastin, resulting in composites with enhanced biological 
properties. Through the use of microfabrication technologies we have enhanced the 
strength and stiffness of collagen matrices, while significantly improving substrate 
extensibility. Excimer laser ablation of collagen matrices resulted in significantly higher 
compliance (9 % - 90 %) with no discernable denaturation, as determined by differential 
scanning calorimetry and transmission electron microscopy. Micro-ablated collagen 
matrices showed enhanced cellular rat bone marrow derived mesenchymal stem cell 
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alignment, as determined by actin staining. This chapter demonstrates how through the 
control of collagen gel hydration, global micro- and macro- structure, and laser ablation 
schemes, a series of strong (on the order of MPa) collagen sheets can be created. The 
result is constructs that have mechanical and biological properties mimicking native 
tissue coupled with cellular alignment and high compliance. Capitalizing on the natural 
abundance of collagen in native tissues, we have designed a bottom-up approach for the 
creation of bioartificial matrices. Through the development and utilization of layer-
reinforced networks and novel microfabrication techniques, we have developed a natural 
biopolymer matrix with tunable mechanical properties suitable for a limitless variety of 
tissue engineering applications: biosynthetic blood vessels, tendon replacements, hernia 
patches, muscle tissue, nerve guidance conduits, artificial skin, and soft tissue 
applications. 
 
In Chapter 4, we further target the development of materials for vascular tissue 
engineering based on prior studies outlined above. Cardiovascular disease (CVD) is the 
leading cause of morbidity and mortality in the United States and many other nations. 
One of the leading causes of CVD is arteriosclerosis, which often requires vessel bypass 
or replacement. Synthetic small diameter vascular grafts can rapidly fail and tissue 
engineered grafts require long fabrication times. Further, there have been only a limited 
number of reports detailing the use of tunable materials for the design of vascular grafts. 
Herein, we propose a hierarchical design of vascular grafts from extracellular matrix 
constituents to recapitulate native tissue structure and function. Through the use of novel 
processing and fabrication schemes for isolated and purified Type I collagen and 
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recombinantly expressed elastin, we have designed large (centimeter scale) 
interpenetrating networks that can be mechanically tailored to match a variety of tissue 
based substrates by the variation of initial collagen and elastin concentrations. Further, 
we show that matrix layering yields an unexpected increase in mechanical properties due 
to network interpenetration and densification. Matrices were tunable to yield a range of 
biologically derived materials that have ultimate tensile strengths ranging from 0.5 – 17 
MPa, and stiffnesses ranging from 2.5 - 120 MPa. Further, we utilize microdomain 
solubilization of genetically engineered recombinant elastin to create viable blood 
contacting matrices. CEMs were embedded with recombinantly expressed elastin, in a 
sandwich molding process. Rolling of embedded matrices was the final step in 
demonstrating the ability to rapidly produce vascular grafts with maintenance of 
characteristic D-periodicity and native collagen structure. Given the native cellular 
adhesivity of collagen, seamless cellularization of CEM matrices could be performed 
with cell adhesion (4 – 12 hours), spreading (12-24 hours) and near confluence being 
reached in 24 hours at a variety of cellularization concentrations. These cellularized 
matrices were embedded in elastin in a rapid, 20 minute, process that resulted in the 
generation of cellularized vascular grafts. This is the first report of cellularized vascular 
grafts generated in 24 hours, with potential for utility in sub-acute care indications. Grafts 
were implanted in a rat aortic interposition model. Histological examination showed that 
implanted vascular grafts show good stability and lack of neointimal hyperplasia, 
aneurysmal dilation or luminal thrombosis/ stenosis. In summary, we have shown the 
ability to create mechanically tunable matrices with in vivo stability and rapid 
cellularization without the addition of foreign cell binding sequences. This work presents 
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a paradigm in the development of extracellular matrix based materials and vascular 
grafts.  
 
5.2 Future Directions 
Strengthening of collagen for greater utility. Collagen matrices can be embedded in a 
variety of polymeric matrices (either biological or synthetic) or co-cast as a gel with other 
matrices – resulting in improved (a) mechanical properties, (b) cytocompatibility, (c) 
biocompatibility and (d) drug delivery potential. The work presented shows how co-
casting with elastin results in interpenetrating networks that have enhanced mechanical 
strength, stiffness and higher strain at failure. Using the large number of labile groups on 
collagen, there is the opportunity to enhance mechanical strength by crosslinking using 
homobifunctional, heterobifunctional or other crosslinking schemes that increase strength 
of matrices, of which genipin is shown in this study.  This has potential utility in other 
tissue engineering applications [306]. Further, it has been suggested that generation of 
large collagen fibrils may enhance mechanical strength [307], and could potentially be 
investigated using different gelation systems, temperatures and mechanisms.  For 
example, freeze dry to induce long crystal formation and structural anisotropy. 
There is the opportunity to form matrices that have incorporated nano-/ micro-particles 
that can act to reinforce structure, dissipate stresses and blunt crack tip propagation (with 
respect to suture pullout). Although particles would be dispersed in a separate phase, 
there is the potential for matrix particle interaction that could further modulate 
mechanical strengths. Specifically, through the incorporation of calcites and other 
apatites, hardness of composites can be enhanced, and hard tissue engineering can be 
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envisioned. Co-casting with mineralized hydroxyapatite and calcium phosphates can 
result in materials with organization, strength, density and hardness mimicking hard 
tissues such as bone [308]. With respect to blood vessels and cartilage, co-casting with 
proteoglycans and glycoaminoglycans would allow for the generation of hydrophilic 
matrices that co-ordinate water molecules to mimic dampening in native tissue.  
 
Enhancing hemocompatibility. Embedment of collagen only matrices or 
interpenetrating networks, depending on the porosity of gels or dried mats, allow for 
creation of composite materials that further enhance mechanical and biological 
suitability. Embedment with recombinantly expressed elastin results in the creation of 
matrices that are resistant to thrombosis (formation of blood clots) and minimal platelet 
adhesion (enhancing its utility of as a blood contacting device), as described in this study. 
However future studies could potentially include the functionalization of cell binding/ 
cell homing sequences to labile groups on collagen or elastin – for example lysine 
residues.  Another example is the use of CD34 antibody (or a host of others) to home and 
conjugate circulating endothelial progenitor cells to graft surfaces [307]. Further, 
functionalization with a variety of other molecular moieties such as thrombomodulin can 
further obviate potential luminal thrombosis [309]. 
 
Use of novel ablation technology for 3D organ tissue fabrication. Given the practical 
spatial resolution of excimer lasers (1-10 µm) and the high fidelity of ablated matrices 
without deleterious effects on collagen scaffold properties, we plan to investigate ablation 
patterns for a variety of tissue engineering applications such as: hierarchical blood vessel 
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cultures, tissue engineered lung (diffusion barrier between alveoli and epithelial cells), 
blood brain barrier replacement, cardiac tissue engineering (as a soft tissue scaffold with 
cardiomyocyte growth in vivo or culture in vitro), localized seeding of cells for liver 
lobule, pancreas and kidney nephron functional unit regeneration, and others. Further, 
based on our initial results, we can create aligned muscle cells on collagen by ablation of 
linear lines on collagen. This will not only enable alignment of cells but potential muscle 
tissue replacement, design of artificial skin, tendon and heart valve leaflets with 
engineered anisotropy, with and without cells. 
 
Collagen / collagen-composite drug delivery vehicles. Work by others in our group has 
shown the potential to conjugate/ trap drugs and small proteins in elastin matrices.  There 
is the ability to create collagen/ CEM matrices that have several labile biologically 
relevant crosslinking groups, as detailed above.  Thus, small molecules, drugs, or nano-/ 
micro-particles can potentially be physically embedded in the collagen/ CEM structure or 
tethered to collagen/ CEM matrix and used for graft-tissue response modulation or 
localized drug delivery. 
 
Acellular and cellularized vascular graft testing. While the grafts tested in the study 
outlined herein were assessed for one week, we propose a series of longer timepoints 
with acellular and cellularized grafts. Specifically, we hope to implant 4 week, 3 month 
and potentially 1 year timepoints that will chronicle the long-term chronic response to the 
implanted vessels in the rat aortic interposition model. 
 137 
 
For the next phase of in vivo testing we plan to implant small diameter grafts (4mm) in a 
pig model. While the pig model better simulates human tissue in size and host tissue 
response, farm breed pigs grow rapidly and “out grow” grafts, resulting in size 
mismatches which may not represent grafts implanted in adult humans. To circumvent 
this, we propose the use of minipig varieties that have a plateau growth curve that better 
simulates human growth [10]. Finally we plan to initiate platelet adhesion/ morphology, 
and hemocompatibility studies in baboon arteriovenous shunt models which will help 
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